51
|
Al-Badri RHO, Sanad SMH, Mekky AEM, Abdelfattah AM. Methicillin-Resistant Staphylococcus aureus Inhibitory Activity of some New Thiazole-Based Schiff Bases: One-pot Synthesis and In Vitro Screening. Chem Biodivers 2025:e202402952. [PMID: 40257681 DOI: 10.1002/cbdv.202402952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2024] [Revised: 02/26/2025] [Accepted: 04/21/2025] [Indexed: 04/22/2025]
Abstract
Twelve thiazole-based Schiff bases derived from salicylaldehyde derivatives are efficiently prepared in the current study. A typical Hantzsch thiazole reaction was used to prepare the targeted molecules in 80%-92%. Therefore, a one-pot protocol was developed involving the reaction of salicylaldehydes, thiosemicarbazide, and the appropriate hydrazonyl chlorides in dioxane at reflux for 5-6 h in the presence of one equivalent of triethylamine. The new products were tested against six different American Type Culture Collection bacterial strains with the reference ciprofloxacin. In general, integrating an aryldiazenyl unit into the structure of the tested 4-methylthiazole-based Schiff bases at thiazole-C5 resulted in improved antibacterial activity. Moreover, Schiff bases linked to 5-((4-chlorophenyl)thio)methyl units outperformed their analogs linked to 5-(phenyl)thio)methyl units by 2-fold. Thiazole-based Schiff base linked to 5-((4-chlorophenyl)thio)methyl and 5-((4-methoxyphenyl)diazenyl) units showed the highest activity against all strains tested, particularly Staphylococcus aureus and Enterococcus faecalis. It had minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) up to 7.4/14.9 µM. Moreover, it demonstrated comparable Methicillin-resistant S. aureus (MRSA) inhibitory activity to linezolid against two MRSA strains with MIC/MBC up to 7.4/29.8 µM.
Collapse
Affiliation(s)
| | - Sherif M H Sanad
- Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt
| | - Ahmed E M Mekky
- Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt
| | | |
Collapse
|
52
|
Minucci R, De Silvestri A, Cambieri P, Corbella M, Pellegrini C, Roda S, Dezza C, Pelenghi S, Bruno R, Belliato M, Seminari E. The Challenge of Bacterial Infections During Intensive Care Unit Stay After Heart Transplantation. Transpl Infect Dis 2025:e70031. [PMID: 40254960 DOI: 10.1111/tid.70031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/22/2025]
Abstract
BACKGROUND Infections occurring in the early post-heart transplant (HT) period heavily contribute to morbidity and mortality. Our goal is to evaluate the incidence of hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAPs) and/or bloodstream infections (BSIs) after HT during the intensive care unit (ICU) stay and identify their associated risk factors in our tertiary hospital. METHODS Observational prospective study including all adult patients who consecutively underwent HT from January 1, 2015 to August 31, 2023 at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. HAP/VAPs and BSIs diagnosed during ICU were included in the analysis. RESULTS A total of 106 patients were included, 38 of whom had at least one infectious episode (35.8%), for a total of 57 independent episodes and their incidence was 2.2 per 100 days (95% CI 1.7-2.8). Length of ICU stay was 8 days (IQR: 6-11) for patients without infectious events and 27 days (IQR 14-52) for those with infectious events (p < 0.001). Gram-negative bacteria were associated with 62.8% of BSIs (mainly Enterobacterales) and with 77.9% of HAP/VAP, in this setting Pseudomonas aeruginosa accounted for 17.6% of infections while Klebsiella spp. accounted for 22.1% of infections. Colonization with resistant bacteria (HR 2.21, 95% CI 1.12-4.35) was associated with increased risk of infections while perioperative antimicrobial prophylaxis (PAP) covering Gram-negative bacteria at transplant (HR 0.45, 95% CI 0.23-0.90, p = 0.023) was a protective factor. CONCLUSION This study shows that Gram-negative infections represent the major challenge for HT patients during ICU stay and shows some evidence in support of the PAP covering Gram-negative infections at transplant.
Collapse
Affiliation(s)
- Rita Minucci
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Annalisa De Silvestri
- SSD Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Patrizia Cambieri
- Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Marta Corbella
- Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Carlo Pellegrini
- Clinical, Surgical, Diagnostic and Pediatric Sciences Department, University of Pavia, Pavia, Italy
- Cardiac Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Silvia Roda
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Chiara Dezza
- Department of SC AR2-Anesthesia and Cardiothoracic ICU, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Stefano Pelenghi
- Cardiac Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Raffaele Bruno
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Mirko Belliato
- Department of SC AR2-Anesthesia and Cardiothoracic ICU, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Elena Seminari
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| |
Collapse
|
53
|
Ikeda S, Watanabe K, Misawa K, Yanagawa N, Hosomi Y. A rapidly progressive case of tuberculous pleurisy and pericarditis in a patient with non-small cell lung cancer that developed one month after receiving pembrolizumab monotherapy. IDCases 2025; 40:e02234. [PMID: 40330577 PMCID: PMC12052681 DOI: 10.1016/j.idcr.2025.e02234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2025] [Revised: 04/18/2025] [Accepted: 04/18/2025] [Indexed: 05/08/2025] Open
Abstract
We report a rapidly progressive case of tuberculous pleurisy and pericarditis. A 59-year-old, male patient with non-small-cell lung cancer commenced pembrolizumab monotherapy one month before but soon thereafter had fevers and dyspnea. Radiography revealed increased right pleural effusion, novel left pleural effusion and cardiomegaly, which had been absent 10 days earlier when a reduction in the target lesion was confirmed. Computed tomography revealed the presence of pericardial fluid. Analysis of the pleural effusion didn't detect malignancy; however, the culture was positive for tuberculosis. It suggests that pembrolizumab may have induced severe inflammation leading to the rapid progression of the disease.
Collapse
Affiliation(s)
- Saori Ikeda
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
| | - Kageaki Watanabe
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
| | - Kazuhito Misawa
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
| | - Noriyo Yanagawa
- Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
| | - Yukio Hosomi
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
| |
Collapse
|
54
|
Xue P, Du X, Kong J. Age-dependent mechanisms of exercise in the treatment of depression: a comprehensive review of physiological and psychological pathways. Front Psychol 2025; 16:1562434. [PMID: 40313907 PMCID: PMC12043869 DOI: 10.3389/fpsyg.2025.1562434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Accepted: 03/31/2025] [Indexed: 05/03/2025] Open
Abstract
Depression has become one of the most common mental disorders in the world. The rising incidence rate and disability rate pose a serious challenge to public health and socio-economic development. Traditional medication and psychotherapy are positive, but they often come with limitations such as side effects, poor compliance, and resource constraints, which highlights the urgent need for more proactive and sustainable non pharmacological interventions. We mainly explored the physiological and psychological mechanisms of exercise in alleviating depression in different age groups. In particular, we evaluated the characteristics and influencing factors of depression in each age group and compared the pathways through which exercise works, aiming to provide scientific basis for clinical practice and public health policies, and strengthen the application of non pharmacological treatment in depression management. It is worth noting that, in the context of a comprehensive search and analysis of recent literature, we have covered the epidemiology of depression, the impact of exercise on mental health, the characteristics of depression in different age groups, and the specific ways in which exercise alleviates depression through physiological and psychological mechanisms. Exercise alleviates symptoms of depression by regulating neurotransmitters, enhancing neuroplasticity, regulating hormone levels, reducing inflammatory responses through physiological pathways, as well as enhancing cognitive function, strengthening emotional regulation, triggering social interactions, and improving self-efficacy through psychological pathways. The differences in physiological and psychological mechanisms among different age groups determine the age dependent characteristics of exercise in mitigating depression. Teenagers, middle-aged people, and elderly people can improve depressive symptoms by enhancing neural progression, regulating stress responses, and strengthening social support, respectively.
Collapse
Affiliation(s)
- Peng Xue
- College of General Education, Shandong Huayu University of Technology, Dezhou, China
| | - Xingbin Du
- College of General Education, Shandong Huayu University of Technology, Dezhou, China
- College of Sports Science, Qufu Normal University, Qufu, China
| | - Jianda Kong
- College of Sports Science, Qufu Normal University, Qufu, China
| |
Collapse
|
55
|
Yang K, Wei H, Zhu W, Xu Y, Wang S, Fan F, Zhang K, Yuan Q, Wang H. Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function. Front Immunol 2025; 16:1559211. [PMID: 40308586 PMCID: PMC12040822 DOI: 10.3389/fimmu.2025.1559211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2025] [Accepted: 03/28/2025] [Indexed: 05/02/2025] Open
Abstract
Background To research the clinical characteristics, risk factors, the correlation between bacterial pulmonary infection and immune function of advanced lung adenocarcinoma patients complicated with bacterial pulmonary infection. Methods 334 stage III and IV lung adenocarcinoma patients admitted to the first affiliated hospital of Zhengzhou University from January 2020 to March 2023 were selected and divided into an infection group (n = 240) and a control group (n= 72) according to whether complicated with bacterial pulmonary infection. The clinical characteristics were analyzed. The pulmonary microbiota and human T lymphocyte subsets (CD3+, CD4+, CD8+) were detected. Multivariate logistic regression analysis was performed to explore the risk factors for pulmonary bacterial infection in advanced lung adenocarcinoma patients. Results Among 334 patients, 264 cases were complicated with pulmonary bacterial infection, and 70 cases had no pulmonary bacterial infection. In total, 544 pathogenic bacteria were isolated from the patients. Of these, 170 strains (31.25%) were Gram-negative bacilli, 162 strains (29.78%) were Gram-positive cocci, 27 strains (4.96%) Gram-positive bacilli. There were statistically significant differences in age, smoking, combined diseases, TNM staging, CD3+ T cell percentage, and CD4+ T cell percentage between the two groups (P < 0.05). Multivariate logistic regression analysis revealed smoking, bronchiectasis, and diabetes were independent risk factors leading to late-stage lung adenocarcinoma patients with bacterial pulmonary infection (P < 0.05). In those patients on immune checkpoint inhibitors, the lung Gram-positive group has a higher number of CD4+ T cells and CD4+/CD8+ T cell ratio than the Gram-negative group (P < 0.05). Conclusion Smoking, bronchiectasis, and diabetes are risk factors for lung bacterial infection in patients with advanced lung adenocarcinoma. The effect of immune checkpoint inhibitor treatment on T cells is more pronounced in Gram positive bacteria.
Collapse
Affiliation(s)
- Kangli Yang
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Haiting Wei
- College of Public Health of Zhengzhou University, Zhengzhou, China
- Gene Hospital of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Weiwei Zhu
- Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Yapeng Xu
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Shuaifeng Wang
- Gene Hospital of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Feifei Fan
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Kai Zhang
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Qing Yuan
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Hongmin Wang
- Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
56
|
Barbarossa L, Zandonà M, Garo ML, Mjahed RB, D’Amelio P. Non-Severe Hypophosphatemia in Older Patients: A Systematic Review. Nutrients 2025; 17:1354. [PMID: 40284219 PMCID: PMC12030319 DOI: 10.3390/nu17081354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2025] [Revised: 04/08/2025] [Accepted: 04/09/2025] [Indexed: 04/29/2025] Open
Abstract
Background/Objectives: Phosphorus plays a fundamental role in cellular and extracellular metabolism, contributing to nucleic acid synthesis, enzymatic activity, neurologic function, and skeletal mineralization. Despite its significance, non-severe hypophosphatemia (HP) remains largely asymptomatic and underdiagnosed, with limited data on its prevalence in the general population. Most studies focus on specific subgroups, such as critically ill or dialysis patients, while the impact of mild HP in older adults, a potentially vulnerable demographic, is not well understood. The objective of this systematic review is to investigate the prevalence and clinical implications of non-severe HP in older adults. Methods: The study followed PRISMA guidelines to assess HP in patients aged ≥ 65 years without critical illnesses or genetic disorders. A systematic search was conducted in PubMed, Web of Science, and Scopus (March 2024). Eligible studies included RCTs and prospective/retrospective studies, excluding cancer-related studies or insufficient phosphate data. Results: We identified 1350 articles, with 26 meeting eligibility criteria. Ultimately, eight studies involving 26,548 patients were included, with an HP prevalence of 12.5%. Studies reveal a higher prevalence of HP in frail individuals, particularly those with increased frailty scores, and an association between HP and cognitive decline, depressed mood, falls, and chronic comorbidities. HP was also prevalent in infectious diseases, especially bacterial pneumonia, with longer hospital stays and increased mortality rates. Malnutrition was significantly more common in HP patients, characterized by weight loss and poor nutritional status. Furthermore, HP increased fall risk during hospitalization and worsened outcomes after coronary artery bypass graft surgery, including higher mortality and graft failure rates, underscoring its clinical importance. Discussion: This review identified that non-severe hypophosphatemia (HP) is associated with conditions such as frailty, cognitive decline, and an increased risk of falls. The evidence suggests that low phosphate levels may negatively impact health, increasing mortality and the risk of adverse clinical outcomes. Despite limitations in diagnostic criteria and sample variability, the findings indicate that HP can be a useful marker for identifying patients at risk of health deterioration. Further research is needed to clearly define the management and treatment of HP in this vulnerable population.
Collapse
Affiliation(s)
- Luca Barbarossa
- Geriatric Service, Clinica Luganese di Moncucco, 6900 Lugano, Switzerland
| | - Martina Zandonà
- Family Medicine Institute, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
| | | | - Ribal Bou Mjahed
- Service of Geriatric Medicine and Geriatric Rehabilitation, Centre Hospitalier Universitaire Vaudois (CHUV), 1005 Lausanne, Switzerland; (R.B.M.); (P.D.)
| | - Patrizia D’Amelio
- Service of Geriatric Medicine and Geriatric Rehabilitation, Centre Hospitalier Universitaire Vaudois (CHUV), 1005 Lausanne, Switzerland; (R.B.M.); (P.D.)
| |
Collapse
|
57
|
Bindel LJ, Seifert R. AWaRe classification analysis for European countries with ARIMA forecasts to assess prescribing patterns and 'One Health' targets. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2025:10.1007/s00210-025-04121-y. [PMID: 40220024 DOI: 10.1007/s00210-025-04121-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2025] [Accepted: 03/28/2025] [Indexed: 04/14/2025]
Abstract
BACKGROUND Antimicrobial resistance is a major threat to public health, with a well-established link between antibacterial consumption and bacterial resistance. Stewardship needs to focus on reducing overall consumption and optimising the quality of prescribing. The European Union's 'One Health' approach aims for at least 65% of antibacterial consumption to be in the 'Access' category of the AWaRe framework until 2030. PURPOSE This study advances the field by shifting the focus from simply quantifying antibacterial consumption to a nuanced assessment of prescribing quality. Prudent and problematic prescribing behaviour is identified in past and projected trends, both for individual countries and European regions. Progress towards the EU's 'One Health' targets for the human sector is assessed and compared with total antibacterial consumption. METHODS This study analyses data from 1997-2023 and predicts future proportions of AWaRe drug classes for European countries until 2030, using the ARIMA(1,0,1) model. The distribution and changes of the AWaRe groups were analysed to assess prescribing behaviour. Total antibacterial consumption is compared with findings of the 'One Health' targets, and bivariate correlation analyses are performed. RESULTS Robust forecast models were developed for the AWaRe classification for 30 European countries. In 2030, the 'Access' group is projected to exceed 65% in Iceland, Denmark, Ireland, Latvia, Finland, France, the Netherlands, Sweden, Lithuania, the United Kingdom, Belgium and Estonia. On the other hand, low shares are expected for Greece (43.8%), Slovakia and Bulgaria (45.9%), Italy (47.3%), Malta (49.9%), Cyprus (50.9%), Hungary (51.8%) and Romania (53.4%). The other 10 countries fall in between, with shares ranging from 56.4% to 64.7%. Of particular concern are Italy, Cyprus and Malta, with low'Access'shares, high consumptions and worsening trends, in contrast to the exemplary performance of Iceland, Norway and Denmark. Germany stands out for its worryingly excessive use of 'Reserve'. Most forecasts were considered reliable, although some showed moderate or poor fit. CONCLUSION The findings predict that many European countries are unlikely to meet the EU's 'One Health' target by 2030. Countries with higher'Access'shares and lower total consumption tend to have lower levels of bacterial resistance, while those with high consumption and problematic prescribing patterns face higher levels of resistance. While most Northern European countries are considered to have a prudent use of medicines, problematic use is observed particularly in Southern and Eastern Europe, a practice being apparent across many medicine classes. Regional differences in prescribing patterns highlight the need for tailored interventions. For certain countries, particularly in Northern Europe, the high proportion of unclassified substances suggests that the AWaRe classification may not fully capture the range of antibacterial substances used.
Collapse
Affiliation(s)
| | - Roland Seifert
- Institute of Pharmacology Hannover Medical School, 30625, Hannover, Germany.
| |
Collapse
|
58
|
Recchia D, Stelitano G, Egorova A, Batisti Biffignandi G, Savková K, Kafková R, Huszár S, Marino Cerrato A, Slayden RA, Cummings JE, Whittel N, Bauman AA, Robertson GT, Rank L, Urbina F, Lane TR, Ekins S, Riabova O, Kazakova E, Mikušová K, Sassera D, Degiacomi G, Chiarelli LR, Makarov V, Pasca MR. Mycobacterium tuberculosis Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound. ACS Infect Dis 2025; 11:986-997. [PMID: 40111403 PMCID: PMC11998004 DOI: 10.1021/acsinfecdis.4c01030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2024] [Revised: 03/13/2025] [Accepted: 03/17/2025] [Indexed: 03/22/2025]
Abstract
Among the critical priority pathogens listed by the World Health Organization, Mycobacterium tuberculosis strains resistant to rifampicin present a significant global threat. Consequently, the study of the mechanisms of resistance to new antitubercular drugs and the discovery of new effective molecules are two crucial points in tuberculosis drug discovery. In this study, we discovered a compound named RCB18350, which is active against M. tuberculosis growth and exhibits a minimum inhibitory concentration (MIC) of 1.25 μg/mL. It was also effective against multidrug-resistant isolates. We deeply studied the mechanism of resistance/action of RCB18350 by using several approaches. We found that Rv3406, an iron- and α-ketoglutarate-dependent sulfate ester dioxygenase, is capable of metabolizing the compound into its inactive metabolite. This finding highlights the role of this enzyme in the mechanism of resistance to RCB18350.
Collapse
Affiliation(s)
- Deborah Recchia
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
| | - Giovanni Stelitano
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
| | - Anna Egorova
- Research
Centre of Biotechnology RAS, Moscow 119071, Russia
| | | | - Karin Savková
- Department
of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, 814 99 Bratislava, Slovakia
| | - Radka Kafková
- Department
of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, 814 99 Bratislava, Slovakia
| | - Stanislav Huszár
- Department
of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, 814 99 Bratislava, Slovakia
| | - Antonio Marino Cerrato
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
| | - Richard A. Slayden
- Mycobacteria
Research Laboratories, Department of Microbiology, Immunology and
Pathology, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Jason E. Cummings
- Mycobacteria
Research Laboratories, Department of Microbiology, Immunology and
Pathology, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Nicholas Whittel
- Mycobacteria
Research Laboratories, Department of Microbiology, Immunology and
Pathology, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Allison A. Bauman
- Colorado
State University, 1682
Campus Delivery, 200 West Lake Street, Fort
Collins, Colorado 80523-1782, United States
| | - Gregory T. Robertson
- Mycobacteria
Research Laboratories, Department of Microbiology, Immunology and
Pathology, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Laura Rank
- Collaborations
Pharmaceuticals, Inc., Raleigh, North Carolina 27606, United States
| | - Fabio Urbina
- Collaborations
Pharmaceuticals, Inc., Raleigh, North Carolina 27606, United States
| | - Thomas R. Lane
- Collaborations
Pharmaceuticals, Inc., Raleigh, North Carolina 27606, United States
| | - Sean Ekins
- Collaborations
Pharmaceuticals, Inc., Raleigh, North Carolina 27606, United States
| | - Olga Riabova
- Research
Centre of Biotechnology RAS, Moscow 119071, Russia
| | - Elena Kazakova
- Research
Centre of Biotechnology RAS, Moscow 119071, Russia
| | - Katarína Mikušová
- Department
of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, 814 99 Bratislava, Slovakia
| | - Davide Sassera
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
- Fondazione
IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Giulia Degiacomi
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
| | - Laurent Robert Chiarelli
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
| | - Vadim Makarov
- Research
Centre of Biotechnology RAS, Moscow 119071, Russia
| | - Maria Rosalia Pasca
- Department
of Biology and Biotechnology “Lazzaro Spallanzani,”, University of Pavia, 27100 Pavia, Italy
- Fondazione
IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| |
Collapse
|
59
|
Dallasheh H, Paul M. Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study. Clin Microbiol Infect 2025:S1198-743X(25)00168-5. [PMID: 40222558 DOI: 10.1016/j.cmi.2025.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2024] [Revised: 03/19/2025] [Accepted: 04/04/2025] [Indexed: 04/15/2025]
Abstract
OBJECTIVES We aimed to quantify the ecological consequences of carbapenems versus piperacillin-tazobactam treatment on the risk of carbapenem-resistant Enterobacterales (CRE) acquisition. METHODS We conducted a retrospective cohort study with propensity-score matching. The study was conducted in a single large hospital in Israel from 2014 to 2023. We included all adult patients treated with piperacillin-tazobactam (PTZ) or a carbapenem for at least 5 days. We excluded patients with known carriage of CRE at treatment initiation and patients in the PTZ group who received a carbapenem within 30 days before or 90 days after the start of PTZ. The outcome assessed was CRE acquisition through surveillance or clinical samples from day 5 to day 90 after treatment initiation. The propensity score for treatment selection was derived to match patients in the treatment groups using 1:1 nearest-neighbour matching with a calliper of 0.01. A sensitivity analysis of the full cohort was performed through a regression model of CRE acquisition, adjusting the analysis using inverse probability of treatment weighting. RESULTS We included 7731 patients, of whom 6.2% (483/7731) acquired CRE: 4.5% (219/4887) of patients treated with PTZ versus 9.3% (264/2844) of patients treated with a carbapenem (unadjusted odds ratio [OR] 0.46, 95% CI, 0.38-0.55). In the matched cohort, CRE acquisition occurred in 6.4% (130/2018) of patients treated with PTZ versus 8.7% (175/2018) of patients treated with carbapenems (propensity score-matched OR 0.72.95% CI, 0.57-0.92). Independent risk factors for CRE acquisition included hospitalization in the haemao-oncology or neurosurgical wards, longer antibiotic exposure and hospitalization, bloodstream infections, low albumin and higher glucose levels. Adjusted to these and weighted by the inverse probability of treatment, PTZ was associated with CRE acquisition with an OR of 0.81, 95% CI, (0.66-0.98). DISCUSSION Carbapenem were significantly associated with CRE acquisition compared with PTZ in a CRE endemic settings.
Collapse
Affiliation(s)
| | - Mical Paul
- Infectious Diseases Division, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
60
|
Lobo-Rodríguez C, Pedraz-Marcos A, Velarde-García JF, Calderari Fernández E, Gadea-Cedenilla C, Medina-Torres M, Moro-Tejedor MN, Sánchez García L, García-Pozo AM. Effectiveness of an Early Intervention in Mild Hyponatremia to Prevent Accidental Falls in Hospitalized Older Adults-A Crossover Ecological Clinical Trial. Healthcare (Basel) 2025; 13:865. [PMID: 40281814 PMCID: PMC12026473 DOI: 10.3390/healthcare13080865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2025] [Revised: 03/31/2025] [Accepted: 04/09/2025] [Indexed: 04/29/2025] Open
Abstract
Background: Falls in hospitalized patients cause injuries of varying severity and even death. There is a link between falls and low blood sodium levels in older patients. Identifying and treating hyponatremia could help prevent falls and reduce hospital stays. The purpose of this study was to evaluate the effectiveness of the correction of hyponatremia on reducing the incidence of falls and the mean stay of hospitalized patients aged more than 65 years. Methods: A crossover ecological clinical trial was conducted in adult hospitalization units of a hospital in Madrid (Spain) over 12 months. Patients meeting inclusion criteria were divided into two randomized groups. The intervention was applied in two six-month phases, alternating between groups with a 15-day washout period. Early diagnosis and treatment of hyponatremia were implemented in the intervention group, while the control group received standard care. Primary outcomes included fall incidence and length of hospital stay. Data were collected using REDCap and analyzed with SPSS v.21. Statistical significance was set at p < 0.05 (ClinicalTrials identifier of the manuscript: NCT03265691). Results: A total of 1925 patients were included (408 intervention, 1517 control). Fall incidence was significantly lower in the intervention group (6.7 vs. 9.8, p = 0.000). Hyponatremia was corrected in 72% of cases. No significant differences were found in functional scores. The intervention effectively reduced falls compared to standard care. Conclusions: Early hyponatremia treatment reduces falls and hospital stay in older patients, supporting its inclusion in fall prevention strategies.
Collapse
Affiliation(s)
- Carmen Lobo-Rodríguez
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- Department of Nursing, Faculty of Nursing, Physiotherapy and Podiatry, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - Azucena Pedraz-Marcos
- Nursing and Healthcare Research Unit (Investén-isciii), Instituto de Salud Carlos III, 28029 Madrid, Spain;
| | - Juan Francisco Velarde-García
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- Research Group in Social Health Care Needs for the Population at Risk of Exclusion, School of Nursing, Red Cross University, Autonomous University of Madrid, 28003 Madrid, Spain
- Research Group of Humanities and Qualitative Research in Health Science of Universidad Rey Juan Carlos (Hum&QRinHS), 28922 Alcorcón, Spain
| | - Elena Calderari Fernández
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
| | - Carmen Gadea-Cedenilla
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- Nurse for Continuity of Care, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
| | - Margarita Medina-Torres
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
| | - Mª Nieves Moro-Tejedor
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- Nursing Research Support Unit, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
| | - Leonor Sánchez García
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
| | - Ana Mª García-Pozo
- Department of Nursing, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; (C.L.-R.); (E.C.F.); (M.M.-T.); (M.N.M.-T.); (L.S.G.); (A.M.G.-P.)
- Research Nursing Group of Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- Department of Nursing, Health Sciences Universidad San Rafael-Nebrija, 28036 Madrid, Spain
| |
Collapse
|
61
|
Czech MM, Cuellar-Rodriguez J, Kwon-Chung KJ, Stock F, Aneke CI, Olivier KN, Fennelly KP, Gea-Banacloche J, Zerbe CS, Freeman AF, Holland SM, Lionakis MS, Seyedmousavi A. Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients. J Clin Microbiol 2025; 63:e0155024. [PMID: 40052805 PMCID: PMC11980389 DOI: 10.1128/jcm.01550-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Accepted: 02/05/2025] [Indexed: 04/10/2025] Open
Abstract
Reduced susceptibility to antifungals is common among members of genera Scedosporium and Lomentospora, with optimal treatments still not fully defined. In vitro antifungal susceptibility results and clinical data do not comprehensively account for the advent of new Scedosporium species identified by molecular phylogenetics. Using Clinical and Laboratory Standards Institute (CLSI) methodology, we tested a total of 103 clinical isolates obtained from patients at the NIH Clinical Center. The most frequent species were Scedosporium apiospermum (63%) and Scedosporium boydii (11%), followed by Lomentospora prolificans (7%). The novel antifungal olorofim showed the lowest MICs against all Scedosporium spp. and L. prolificans, followed by micafungin. Among the triazoles, voriconazole showed lower MICs against Scedosporium spp. Amphotericin B and posaconazole demonstrated species-specific and inter-species variable activity. Itraconazole, isavuconazole, and terbinafine had higher MIC values against Scedosporium spp. and L. prolificans. Clinical data were retrospectively reviewed for 90 isolates, of which nine patients (28 isolates) had active disease/infection and received antifungal treatment that included voriconazole or posaconazole. Five of these patients (56%) died, while three patients (33%) with chronic granulomatous disease were cured following hematopoietic cell transplantation. In 24 patients (62 isolates), the presence of the fungus was considered airway colonization. In conclusion, our data support the existence of species-specific and inter-species differences in the antifungal susceptibility patterns among members of genera Scedosporium and L. prolificans. The novel investigational antifungal olorofim may be a promising therapy. Our clinical data suggest that host status and administration of antifungal therapy most effective for each Scedosporium species complex are important determinants of outcomes.IMPORTANCEUnderstanding the epidemiology and clinical spectrum of infections caused by Scedosporium species complex and Lomentospora prolificans is integral to improving outcomes, particularly in severely ill and immunocompromised patients. In vitro antifungal susceptibility testing can provide an estimate of antifungal activity against fungal pathogens. Our study showed that species-specific and inter-species differences exist in the distribution of antifungal susceptibility patterns between Scedosporium and L. prolificans. Our clinical data also highlight that host status, along with effective antifungal therapy, plays a crucial role in determining treatment outcomes.
Collapse
Affiliation(s)
- Mary M. Czech
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Jennifer Cuellar-Rodriguez
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Kyung J. Kwon-Chung
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Frida Stock
- Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Chioma I. Aneke
- Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Kenneth N. Olivier
- Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Kevin P. Fennelly
- Pulmonary Clinical Medicine Section, Cardiovascular Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Juan Gea-Banacloche
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Christa S. Zerbe
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Alexandra F. Freeman
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Steven M. Holland
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Michail S. Lionakis
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Amir Seyedmousavi
- Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
62
|
Mwaturura T, Olaru ID, Chimhini G, Bwakura-Dangarembizi M, Mangiza M, Chimhuya S, Sado B, Katunga J, Tarupiwa A, Juru A, Mashe T, Pasi C, Chuchu V, Gansallo S, Gleeson B, Fitzgerald F, Ferreyra C, Kranzer K. Rapid bacterial identification and resistance detection using a low complexity molecular diagnostic platform in Zimbabwe. PLOS GLOBAL PUBLIC HEALTH 2025; 5:e0004343. [PMID: 40202992 PMCID: PMC11981161 DOI: 10.1371/journal.pgph.0004343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Accepted: 02/05/2025] [Indexed: 04/11/2025]
Abstract
BACKGROUND Sepsis is a major cause of mortality in low-resource settings. Effective microbiological culture services are a bottleneck in diagnosis and surveillance. AIM We aimed to evaluate the performance of the BIOFIRE FILMARRAY Blood Culture Identification 2 (BCID2, bioMérieux) assay in a low-resource setting laboratory in comparison to standard practice. METHODS This five month prospective validation study included all positive blood cultures collected at Sally Mugabe Central Hospital, Harare, Zimbabwe. BCID2 testing was done in parallel to standard phenotypic procedures and resistance testing. Reference identification was performed using mass spectrometry or whole genome sequencing. Only samples with available reference standard results were included in the analysis. Data captured on paper-based forms was entered into electronic case report forms (ODK Collect). Specificity and sensitivity for BCID2 were calculated in comparison to the reference standards, with performance measures calculated using the Wilson score. Biomedical scientists using BCID2 completed a system usability survey (SUS). RESULTS Positive results were recorded in 780/2,023 (38.5%) blood cultures, within which 377 (48.3%) had reference results and so were included in analysis. Neonatal samples were most frequent (182, 48.3%), then paediatric (150, 39.8%), then adults (18, 4.8%) and unknown (27, 7.2%). Specificity exceeded 95% throughout. Sensitivity ranged from 50% (A. calcoaceticus-baumanii complex, Proteus spp.) to 100% (S. pneumoniae, Salmonella spp). Using BCID2, CTX-M was detected in 111/175 (74.5%) Enterobacterales, from which 5/111 also had NDM and VIM detected. NDM-5 was detected in 2/5 NDM samples using sequencing. In total 3/23 S. aureus isolates were methicillin resistant, from which one was confirmed using phenotypic antimicrobial susceptibility testing. Usability was good (SUS score = 79.5). CONCLUSION Rapid molecular tests have potential to improve turn-around time and quality of sepsis diagnostics. However, specific work-flows are critical to supplement molecular tests with minimal phenotypic tests for optimal clinical decision-making.
Collapse
Affiliation(s)
- Tinashe Mwaturura
- The Health Research Unit, Biomedical Research and Training Institute, Harare, Zimbabwe
- Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Ioana D. Olaru
- Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Institute of Medical Microbiology, University Hospital Münster, Münster, Germany
| | - Gwendoline Chimhini
- Department of Child, Adolescent and Women’s Health, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe
| | - Mutsa Bwakura-Dangarembizi
- Department of Child, Adolescent and Women’s Health, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe
| | | | - Simbarashe Chimhuya
- Department of Child, Adolescent and Women’s Health, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe
| | | | | | - Andrew Tarupiwa
- National Microbiology Reference Laboratory, AMR unit, Harare, Zimbabwe
| | - Agnes Juru
- National Microbiology Reference Laboratory, AMR unit, Harare, Zimbabwe
| | - Tapfumaneyi Mashe
- National Microbiology Reference Laboratory, AMR unit, Harare, Zimbabwe
| | | | - Veronicah Chuchu
- Foundation of Innovative Diagnostics, Medical Affairs Department, Geneva, Switzerland
| | - Seyi Gansallo
- Foundation of Innovative Diagnostics, Medical Affairs Department, Geneva, Switzerland
| | - Birgitta Gleeson
- Foundation of Innovative Diagnostics, Medical Affairs Department, Geneva, Switzerland
| | - Felicity Fitzgerald
- The Health Research Unit, Biomedical Research and Training Institute, Harare, Zimbabwe
- Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, United Kingdom
| | - Cecilia Ferreyra
- Foundation of Innovative Diagnostics, Medical Affairs Department, Geneva, Switzerland
| | - Katharina Kranzer
- The Health Research Unit, Biomedical Research and Training Institute, Harare, Zimbabwe
- Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU, Munich, Germany
| |
Collapse
|
63
|
Zhou H, Jia C, Shen P, Huang C, Teng L, Wu B, Wang Z, Wang H, Xiao Y, Baker S, Weill FX, Li Y, Yue M. Genomic census of invasive nontyphoidal Salmonella infections reveals global and local human-to-human transmission. Nat Med 2025:10.1038/s41591-025-03644-4. [PMID: 40205197 DOI: 10.1038/s41591-025-03644-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Accepted: 03/05/2025] [Indexed: 04/11/2025]
Abstract
Extraintestinal infections caused by Enterobacteriaceae represent a global concern, further exacerbated by the growing prevalence of antimicrobial resistance (AMR). Among these, invasive nontyphoidal Salmonella (iNTS) infections have become increasingly challenging to manage, and their global spread remains poorly understood. Here we compiled 1,115 patient records and generated a comprehensive genomic dataset on iNTS. Age and sex emerged as significant risk factors, with Salmonella Enteritidis identified as a major cause. We observed serovar-specific AMR patterns, with notable resistance to fluoroquinolones and third-generation cephalosporins. A global phylogenomic analysis of Enteritidis revealed three distinct clades, highlighting the accumulation of AMR determinants during its international spread. Importantly, our genomic and transmission analyses suggest that iNTS infections may involve human-to-human transmission, with diarrheal patients acting as potential intermediaries, deviating from typical zoonotic pathways. Collectively, our newly generated cohort and iNTS genomic dataset provide a framework for precise local iNTS burden and underscore emerging transmission trends.
Collapse
Affiliation(s)
- Haiyang Zhou
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China
| | - Chenghao Jia
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China
| | - Ping Shen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China
| | - Chenghu Huang
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China
| | - Lin Teng
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China
| | - Beibei Wu
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China
| | - Zining Wang
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China
| | - Haoqiu Wang
- Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
| | - Yonghong Xiao
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China
| | - Stephen Baker
- School of Clinical Medicine, University of Cambride, Cambridge, UK
| | - François-Xavier Weill
- Institut Pasteur, Université Paris Cité, Unité des Bactéries pathogènes entériques, Paris, France
| | - Yan Li
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China
| | - Min Yue
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, People's Republic of China.
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, People's Republic of China.
- Hainan Institute of Zhejiang University, Sanya, People's Republic of China.
| |
Collapse
|
64
|
García-Masedo Fernández S, Laporta R, Aguilar M, García Fadul C, Cabrera Pineda M, Alastruey-Izquierdo A, Royuela A, Sánchez Romero I, Ussetti Gil P. Clinical Significance and Therapeutic Challenges of Scedosporium spp. and Lomentospora prolificans Isolates in a Single-Center Cohort of Lung Transplant Recipients. J Fungi (Basel) 2025; 11:291. [PMID: 40278112 PMCID: PMC12028535 DOI: 10.3390/jof11040291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Revised: 04/04/2025] [Accepted: 04/05/2025] [Indexed: 04/26/2025] Open
Abstract
(1) Background: Emerging fungal infections associated with Scedosporium spp. and Lomentospora prolificans (S/L) are becoming more frequent and are very difficult to treat. Our objective was to analyze the frequency and management of S/L isolates in lung transplant (LTx) recipients, the patient outcomes and in vitro antifungal sensitivity. (2) Methods: We included all patients with S/L isolation during post-transplant follow-up. Data were collected from electronic medical records. All samples were cultivated on Sabouraud Chloramphenicol agar. Isolations of S/L were submitted to in vitro susceptibility tests. (3) Results: A total of 11 (2%) of the 576 LTx recipients included had at least one isolation of S/L. Classification for the 11 cases were colonization (4; 36%) and infection (7; 65%). Five infections were pulmonary (71%) and two were disseminated (29%). S. apiospermum complex was the most frequently occurring isolation in patients with pulmonary disease while L. prolificans was the most frequent in patients with disseminated disease. Ten patients were treated. The most frequent antifungal drugs used were voriconazole (n = 8) and terbinafine (n = 6). Seven patients (70%) received more than one drug. The mortality rate associated with L. prolificans isolation was 50% for colonization and 100% for disseminated disease. (4) Conclusions: Scedosporium spp. and L. prolificans infections are associated with high morbidity and mortality rates. New diagnostic and therapeutic tools are required to reduce the impact of these infections.
Collapse
Affiliation(s)
| | - Rosalía Laporta
- Pneumology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (R.L.); (M.A.); (C.G.F.); (P.U.G.)
| | - Myriam Aguilar
- Pneumology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (R.L.); (M.A.); (C.G.F.); (P.U.G.)
| | - Christian García Fadul
- Pneumology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (R.L.); (M.A.); (C.G.F.); (P.U.G.)
| | - María Cabrera Pineda
- Microbiology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (M.C.P.); (I.S.R.)
| | - Ana Alastruey-Izquierdo
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain;
| | - Ana Royuela
- Clinical Biostatistics Unit, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, 28222 Majadahonda, Madrid, Spain;
| | - Isabel Sánchez Romero
- Microbiology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (M.C.P.); (I.S.R.)
| | - Piedad Ussetti Gil
- Pneumology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain; (R.L.); (M.A.); (C.G.F.); (P.U.G.)
| |
Collapse
|
65
|
Oyovwi MO, Ben-Azu B, Babawale KH. Therapeutic potential of microbiome modulation in reproductive cancers. Med Oncol 2025; 42:152. [PMID: 40188410 DOI: 10.1007/s12032-025-02708-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2025] [Accepted: 03/30/2025] [Indexed: 04/08/2025]
Abstract
The human microbiome, a complex ecosystem of microbial communities, plays a crucial role in physiological processes, and emerging research indicates a potential link between it and reproductive cancers. This connection highlights the significance of understanding the microbiome's influence on cancer development and treatment. A comprehensive review of current literature was conducted, focusing on studies that investigate the relationship between microbiome composition, reproductive cancer progression, and potential therapeutic approaches to modulate the microbiome. Evidence suggests that imbalances in the microbiome, known as dysbiosis, may contribute to the development and progression of reproductive cancers. Specific microbial populations have been associated with inflammatory responses, immune modulation, and even resistance to conventional therapies. Interventions such as probiotics, dietary modifications, and fecal microbiota transplantation have shown promise in restoring healthy microbiome function and improving cancer outcomes in pre-clinical models, with pilot studies in humans indicating potential benefits. This review explores the therapeutic potential of microbiome modulation in the management of reproductive cancers, discussing the mechanisms involved and the evidence supporting microbiome-targeted therapies. Future research is warranted to unravel the complex interactions between the microbiome and reproductive cancer pathophysiology, paving the way for innovative approaches.
Collapse
Affiliation(s)
- Mega Obukohwo Oyovwi
- Faculty of Basic Medical Sciences, Department of Physiology, Adeleke University, Ede, Osun State, Nigeria.
- Department of Human Physiology, Faculty of Basic Medical Sciences, Delta State University of Science and Technology, Ozoro, Delta State, Nigeria.
| | - Benneth Ben-Azu
- DELSU Joint Canada-Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Delta State University, Abraka, 330106, Delta State, Nigeria
| | - Kehinde Henrietta Babawale
- Faculty of Basic Medical Sciences, Department of Physiology, Adeleke University, Ede, Osun State, Nigeria
| |
Collapse
|
66
|
Dolatkhah Laein G, Raeesi J, Mokhtari A, Salehinia O, Mehri M, Shilanath Tiwary U. Telemedicine interventions for improving antibiotic stewardship and prescribing: A systematic review. PLoS One 2025; 20:e0320840. [PMID: 40179108 PMCID: PMC11967954 DOI: 10.1371/journal.pone.0320840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2024] [Accepted: 02/25/2025] [Indexed: 04/05/2025] Open
Abstract
The global antibiotic resistance crisis necessitates optimized stewardship programs, with telemedicine emerging as a promising delivery strategy. This systematic review evaluated the effectiveness of telemedicine interventions in improving antibiotic stewardship across clinical settings. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched seven databases from January 2010 to July 2024. Two independent reviewers assessed studies using Risk of Bias in Non-randomized Studies (ROBINS-I) and Cochrane Risk of Bias 2.0 tools, with evidence certainty evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Twenty-one studies met inclusion criteria (10 observational, 8 quasi-experimental, 2 Randomized Controlled Trials [RCTs], 1 mixed-methods), predominantly from the United States (57.0%, n = 12). Among studies reporting antibiotic use outcomes (52.4%, n = 11), 90.9% demonstrated significant reductions ranging from 5.3% to 62.7%, with the highest-quality evidence showing a 28% reduction (95% Confidence Interval [CI]: 22-34%). Guideline adherence studies (57.1%, n = 12) showed acceptance rates of 67.7% to 98%, with comparable effectiveness between telemedicine and in-person consultation (79.1% vs 80.4%, p = 0.36). Prescribing rate outcomes (38.1%, n = 8) revealed setting-dependent variations: inpatient implementations demonstrated significant reductions (Relative Risk [RR] 0.68; 95% CI: 0.63-0.75), while outpatient findings showed mixed results. Quality assessment revealed predominantly low risk of bias [ROB] (66.7%, n = 14). These findings suggest that telemedicine effectively improves antibiotic stewardship compared to traditional care models, particularly in hospital settings, while outpatient applications demonstrated variable effectiveness. This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023454663).
Collapse
Affiliation(s)
| | - Javad Raeesi
- Health and Rehabilitation Sciences, The University of Western Ontario, London, Ontario, Canada
| | - Ali Mokhtari
- Department of Biology, Faculty of Science, Islamic Azad University of Mashhad, Mashhad, Iran
| | - Omid Salehinia
- Department of Electrical and Electronics Engineering, Ferdowsi University of Mashhad, Mashhad, Iran
| | | | | |
Collapse
|
67
|
Devauchelle P, Bignon A, Breteau I, Defaye M, Degravi L, Despres C, Godon A, Guérin R, Lavayssiere L, Lebas B, Maurice A, Monet C, Monsel A, Reydellet L, Roullet S, Rozier R, Guichon C, Weiss E. Perioperative Management During Liver Transplantation: A National Survey From the French Special Interest Group in "Liver Anesthesiology and Intensive Care". Transplantation 2025; 109:671-680. [PMID: 40071909 DOI: 10.1097/tp.0000000000005264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/26/2025]
Abstract
BACKGROUND Perioperative management practices in liver transplantation (LT) evolve very quickly. There are few specific recommendations, often based on a low level of evidence, resulting in wide heterogeneity of practices. METHODS We performed a survey in all 16 French centers in 2021 by focusing on center organization, preoperative cardiovascular assessment, antimicrobial prophylaxis, hemostasis management, intraoperative use of hemodynamic monitoring and renal replacement therapy, immunosuppression, and postoperative prevention of arterial complications and compared it with current recommendations. RESULTS The organization of perioperative LT care involved 1 single team throughout the perioperative LT process in 7 centers (43.7%). The coronary evaluation was systematic in one-third of the centers and guided by risk factors in the other centers. Antibiotic prophylaxis was strictly intraoperative in only 7 centers (44%). Antifungal prophylaxis targeting high-risk LT recipients was administered in 15 centers (93%). Intraoperative coagulation assessment was based on standard coagulation tests in 8 centers (50%), on viscoelastic assays in 4 centers (25%), and both methods in 4 centers (25%). Hemodynamic monitoring practices greatly varied between centers.Concerning immunosuppression, molecules and dosages were heterogeneous. Aspirin was systematically administered in one-third of cases (6 centers; 37.5%). Of the 21 recommendations tested, the concordance rate was 100% for 3 recommendations and <50% for 7 recommendations. CONCLUSIONS Our study precisely describes French practices regarding LT in perioperative care and highlights the paucity of data in this setting, leading to very weak recommendations that are poorly followed in LT centers.
Collapse
Affiliation(s)
- Pauline Devauchelle
- Department of Anaesthesiology and Critical Care, Hôpital Beaujon, AP-HP, Clichy, France
| | - Anne Bignon
- CHU Lille, Surgical Critical Care and Hepatic Transplant Unit, Department of Anesthesia Critical Care and Perioperative Medicine, Lille, France
| | - Isaure Breteau
- Department of Anesthesia and Surgical Intensive Care Unit, Tours University Hospital, Tours, France
| | - Mylène Defaye
- Department of Anaesthesia and Intensive Care, Bordeaux University Hospital, Pessac, France
| | - Laurianne Degravi
- Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, France
| | - Cyrielle Despres
- Department of Anaesthesia and Intensive Care, Minjoz Hospital, Besançon University Hospital, Besançon, France
| | - Alexandre Godon
- Department of Anaesthesia and Intensive Care, University of Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France
| | - Renaud Guérin
- Service De Réanimation Adultes, Unité de Soins Continus et Unité de Transplantation Hépatique, pôle MPO, CHU Estaing, Clermont-Ferrand, France
| | - Laurence Lavayssiere
- Intensive Care Unit, Department of Transplantation, Rangueil University Hospital, Toulouse, France
| | - Benjamin Lebas
- Department of Anesthesiology, Intensive Care and Perioperative Medicine, Hautepierre Hospital, Strasbourg University Hospital, Strasbourg, France
| | - Axelle Maurice
- Département d'Anesthésie réanimation chirurgicale, CHU Pontchaillou, Rennes, France
| | - Clément Monet
- Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, France
| | - Antoine Monsel
- Sorbonne Université-INSERM UMRS_959, Immunology-Immunopathology-Immunotherapy, Paris, France
- Biotherapy (CIC-BTi), La Pitié-Salpêtrière Hospital, Greater Paris University Hospitals, Paris, France
- UMRS-938, Research Center of Saint-Antoine (CRSA), Sorbonne University, Paris, France
- Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care, La Pitié-Salpêtrière Hospital, Greater Paris University Hospitals, Sorbonne University, Paris, France
| | - Laurent Reydellet
- Service d'Anesthésie-Réanimation, Réanimation Polyvalente et Pathologie du Foie, APHM, C.H.U. Timone, Marseille, France
| | - Stéphanie Roullet
- Département d'Anesthésie Réanimation, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Villejuif, France
- Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITH U1176, Le Kremlin-Bicêtre, France
| | - Romain Rozier
- Department of Anesthesia and Intensive Care, University of Cöte d'Azur, University Hospital Archer 2, Nice, France
| | - Céline Guichon
- Service d'Anesthésie-Réanimation, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Emmanuel Weiss
- Department of Anaesthesiology and Critical Care, Université de Paris, Hôpital Beaujon, AP-HP, Clichy, France
| |
Collapse
|
68
|
Maduranga S, Shrestha LB, Valencia BM, Horton G, Guppy M, Gidding HF, Graves S, Stenos J, Rawlinson W, Lloyd AR, Rodrigo C. Diagnosing and Preventing Q Fever in Regional New South Wales, Australia-A Qualitative Exploration of Perspectives of General Practitioners. Aust J Rural Health 2025; 33:e70030. [PMID: 40084595 PMCID: PMC11907686 DOI: 10.1111/ajr.70030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Revised: 03/05/2025] [Accepted: 03/08/2025] [Indexed: 03/16/2025] Open
Abstract
OBJECTIVE To qualitatively explore the perceptions of general practitioners in regional New South Wales, Australia, on diagnosing, managing and preventing Q fever. SETTING Q fever is a prevalent zoonosis in regional New South Wales, but diagnosis may be missed as patients have symptoms similar to influenza or COVID. Perspectives of general practitioners who are the primary health care providers in rural areas are important to understand the logistical difficulties in providing optimum care to Q fever patients. PARTICIPANTS General practitioners practicing outside of metropolitan Sydney in regional postcodes of New South Wales, Australia. METHODS Eligible general practitioners were interviewed online using a semi-structured interview guide on their approach to diagnosis, management and prevention of Q fever. The data were transcribed, coded using NVivo software, and analysed to identify emerging overarching themes. RESULTS Thematic saturation was achieved after 11 interviews. Diagnostic delays due to prioritising more common differential diagnoses for an influenza-like illness, difficulties in navigating the complex serological test interpretations for diagnosis, logistical difficulties in arranging immunisation, and the need for continuing medical education were the broad themes emerging from the data analysis. CONCLUSIONS Investment in continuing medical education and expansion of the reference resources made available to general practitioners regarding the diagnosis and management of Q fever will improve health care for people suffering from and at risk of Q fever in regional New South Wales.
Collapse
Affiliation(s)
- Sachith Maduranga
- School of Biomedical SciencesUNSW SydneySydneyNew South WalesAustralia
| | | | | | - Graeme Horton
- School of Medicine and Public HealthUniversity of NewcastleNew South WalesAustralia
| | - Michelle Guppy
- School of Rural MedicineUniversity of New EnglandArmidaleNew South WalesAustralia
| | | | - Stephen Graves
- Australian Rickettsial Reference LaboratoryGeelongVictoriaAustralia
| | - John Stenos
- Australian Rickettsial Reference LaboratoryGeelongVictoriaAustralia
| | - William Rawlinson
- School of Biomedical SciencesUNSW SydneySydneyNew South WalesAustralia
| | | | - Chaturaka Rodrigo
- School of Biomedical SciencesUNSW SydneySydneyNew South WalesAustralia
- Kirby InstituteUNSW SydneySydneyNew South WalesAustralia
| |
Collapse
|
69
|
Mantri T, Burad J, Hashmi SA, Jaadi SSAA, Aladawi B, Balushi WAS. A Retrospective Closed Cohort Study on Distribution of Multidrug-Resistant Bacteria in Ventilator-Associated Pneumonia and its Impact on Patient Outcome. J Intensive Care Med 2025; 40:410-417. [PMID: 39444321 DOI: 10.1177/08850666241290468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2024]
Abstract
Objectives: Ventilator-associated pneumonia (VAP) is a common and serious nosocomial infection affecting critically ill patients undergoing mechanical ventilation. This study investigated the prevalence of multidrug-resistant (MDR) organisms in VAP, the VAP rate, and the outcomes associated with MDR-VAP. Methods: This retrospective single-center study, conducted in 2022, included adult ICU cases from April 2021 to March 2022, receiving mechanical ventilation for more than 48 h. Patient data were analyzed for demographics, comorbidities, empirical antibiotic use, and outcomes. MDR organisms were identified in respiratory cultures. Results: Among 447 patients, 133 developed VAP, with 96 cases being MDR-VAP. The mean age of the overall VAP population was 52 years, 70% of which were males. The incidence of VAP was 30.0% (95% CI: 25.7%-34.5%), while that of MDR-VAP was 21.6% (95% CI: 17.9%-25.8%). The most prevalent MDR organisms were Acinetobacter species (50%) and Klebsiella pneumoniae (46.9%). Empirical antibiotics were administered in 96% of VAP cases. The overall VAP rate was 38.03/1000 ventilator days. No single antimicrobial agent seemed to offer an empirical cover, as the susceptibility rate for most tested antimicrobials was less than 85%. Patients with MDR-VAP had a low survival rate (64.6%) and were less likely to be extubated at 13.5% compared to non-MDR-VAP (survival rate of 62.2%). COVID-19 patients had a high incidence of MDR VAP, especially with Acinetobacter. Overall, VAP mortality was 57.1%. The median ventilator days were 16 for VAP and only four for non-VAP. Conclusion: Gram-negative organisms, particularly Klebsiella and Acinetobacter, were the main MDR VAP culprits. MDR-VAP exhibited higher morbidity and mortality. A study focused on developing resistance by microorganisms is warranted for further understanding.
Collapse
Affiliation(s)
- Tushar Mantri
- Department of Anesthesia and Intensive Care, SQUH, Muscat, Oman
| | - Jyoti Burad
- Department of Anesthesia and Intensive Care, SQUH, Muscat, Oman
| | - Safiya Al Hashmi
- Department of Anesthesia, Oman Medical Specialty Board, Muscat, Oman
| | | | | | | |
Collapse
|
70
|
Al-Hashimy ZS, Al-Yaqoobi M, Jabari AA, Kindi NA, Kazrooni ASA, Conway BR, Elhajji FD, Bond SE, Lattyak WJ, Aldeyab MA. Threshold modeling for antibiotic stewardship in Oman. Am J Infect Control 2025; 53:514-519. [PMID: 39549748 DOI: 10.1016/j.ajic.2024.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2024] [Revised: 11/07/2024] [Accepted: 11/08/2024] [Indexed: 11/18/2024]
Abstract
BACKGROUND Antimicrobial stewardship supports rational antibiotic use. However, balancing access to antibiotic treatment while controlling resistance is challenging. This research used a threshold logistic modeling approach to identify targets for antibiotic usage associated with carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Klebsiella pneumonia, and extended-spectrum β-lactamases-producing Escherichia coli incidence in hospitals. METHODS This study utilizes an ecological population-level design. Monthly pathogen cases and antibiotic use were retrospectively determined for inpatients between January 2015 and December 2023. The hospital pharmacy and microbiology information systems were used to obtain this data. Thresholds were identified by applying nonlinear modeling and logistic regression. RESULTS Incidence rates of 0.199, 0.175, and 0.146 cases/100 occupied bed-days (OBD) for carbapenem-resistant A baumannii, carbapenem-resistant K pneumonia, and extended-spectrum β-lactamases-producing E coli, respectively, were determined as the cutoff values for high (critical) incidence rates. Thresholds for aminoglycosides (0.59 defined daily dose [DDD]/100 OBD), carbapenems (6.31 DDD/100 OBD), piperacillin-tazobactam (3.71 DDD/100 OBD), third-generation cephalosporins (3.71 DDD/100 OBD), and fluoroquinolones (1.91 DDD/100 OBD), were identified. Exceeding these thresholds would accelerate the gram-negative pathogens' incidence rate above the critical incidence levels. CONCLUSIONS Threshold logistic models can help inform and implement effective antimicrobial stewardship interventions to manage resistance within hospital settings.
Collapse
Affiliation(s)
- Zainab Said Al-Hashimy
- Department of Clinical Pharmacy, Directorate of Pharmaceutical Care and Medical Stores, Khawlah Hospital, Muscat, Oman; Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK
| | - Mubarak Al-Yaqoobi
- Department of Microbiology, Directorate of Laboratories, Khawlah Hospital, Muscat, Oman
| | - Amal Al Jabari
- Department of Microbiology, Directorate of Laboratories, Khawlah Hospital, Muscat, Oman
| | - Nawal Al Kindi
- Department of Microbiology, Directorate of Laboratories, Khawlah Hospital, Muscat, Oman; Directorate of Infection Prevention and Occupational Safety, Khawlah Hospital, Muscat, Oman
| | - Ahmed Saleh Al Kazrooni
- Department of Microbiology, Directorate of Laboratories, Khawlah Hospital, Muscat, Oman; Directorate of Infection Prevention and Occupational Safety, Khawlah Hospital, Muscat, Oman
| | - Barbara R Conway
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK; Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield, UK
| | | | - Stuart E Bond
- Pharmacy Department, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK
| | - William J Lattyak
- Statistical Consulting Department, Scientific Computing Associates Corp, River Forest, IL, USA
| | - Mamoon A Aldeyab
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK; Pharmacy Department, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.
| |
Collapse
|
71
|
Fuller H, Tittanegro TH, Maini AA, China L, Rhodes F, Becares Salles N, Mukhopadhyay S, Moore B, O’Brien A. Hyperbilirubinemia at hospitalization predicts nosocomial infection in decompensated cirrhosis: Data from ATTIRE trial. Hepatol Commun 2025; 9:e0648. [PMID: 40126412 PMCID: PMC11927652 DOI: 10.1097/hc9.0000000000000648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Accepted: 10/11/2024] [Indexed: 03/25/2025] Open
Abstract
BACKGROUND To identify clinical characteristics and serological biomarkers that predicted subsequent nosocomial infection in ATTIRE trial patients. METHODS We identified 360 patients at hospitalization without infection and not prescribed antibiotics and compared clinical characteristics between those who subsequently developed a nosocomial infection and not. In a 68-patient subcohort, we compared plasma biomarkers of bacterial translocation, infection, and inflammation at hospitalization between those who developed a nosocomial infection and not. In a 56-patient subcohort, we investigated plasma lipidomic profiles in those who did and did not develop nosocomial infection using Lipotype Shotgun platform analysis and multivariate statistical techniques. To further investigate lipid pathways, we compared outcomes in patients taking statins or not at hospitalization. RESULTS Serum bilirubin >188 µmol/L at hospitalization predicted subsequent nosocomial infection in univariate and multivariate analyses, with 80% specificity. The most common nosocomial infections were respiratory tract (29%) and those developing infection had significantly greater 28 and 90-day mortality than those not (p=9.34E-05 and 0.014). Serological biomarkers of bacterial translocation, infection, and inflammation did not predict subsequent infection. Partial least squares discriminatory analyses identified cholesterol esters (CEs) (CE.18.1.2, CE.18.1.0, and CE.16.0.0) as important predictors of infection but provided only a small improvement in predictive ability over bilirubin alone. RNA-sequencing analyses suggest this is mediated by a downregulation of the cellular cholesterol esterification enzyme sterol O-acyltransferase 1. Statin use was not associated with nosocomial infection prevention. CONCLUSIONS In ATTIRE, elevated serum bilirubin at hospitalization was the only clinical characteristic that predicted subsequent development of nosocomial infection. Considering the rising incidence of antimicrobial resistance, these data could be used to limit antibiotic prophylaxis or aid trial design for investigating use in high-risk patients.
Collapse
Affiliation(s)
- Harriett Fuller
- School of Food Science and Nutrition, University of Leeds, Leeds, UK
| | - Thais H. Tittanegro
- Division of Medicine, UCL Institute for Liver and Digestive Health, London, UK
| | - Alexander A. Maini
- Division of Medicine, UCL Institute for Liver and Digestive Health, London, UK
| | - Louise China
- Division of Medicine, UCL Institute for Liver and Digestive Health, London, UK
| | - Freya Rhodes
- Division of Medicine, UCL Institute for Liver and Digestive Health, London, UK
| | | | - Subhankar Mukhopadhyay
- Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London Strand London, UK
| | - Bernadette Moore
- School of Food Science and Nutrition, University of Leeds, Leeds, UK
| | - Alastair O’Brien
- Division of Medicine, UCL Institute for Liver and Digestive Health, London, UK
- Comprehensive Clinical Trials Unit, University College London, UK
| |
Collapse
|
72
|
Jiminez V, Catinis A, Orengo I, Nunez-Gussman J. Murine typhus: An unlikely cause of cat scratch fever with ascending rash. JAAD Case Rep 2025; 58:15-17. [PMID: 40099173 PMCID: PMC11910497 DOI: 10.1016/j.jdcr.2024.12.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2025] Open
Affiliation(s)
- Victoria Jiminez
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
| | - Anna Catinis
- Department of Dermatology, Baylor College of Medicine, Houston, Texas
| | - Ida Orengo
- Department of Dermatology, Baylor College of Medicine, Houston, Texas
| | | |
Collapse
|
73
|
Tang R, Jin Y, Xu K, Wu L, Chen X, Guo Y, Li G, Li J. Aberrant functional connectivity patterns in the pregenual anterior cingulate cortex and anterior midcingulate cortex of patients with irritable bowel syndrome accompanied by depressive symptoms. Brain Imaging Behav 2025; 19:279-290. [PMID: 39775692 DOI: 10.1007/s11682-024-00964-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2024] [Indexed: 01/11/2025]
Abstract
Irritable bowel syndrome (IBS) is a common brain-gut disorder often accompanied by depressive symptoms, with atrophy and hyperactivity of the anterior cingulate gyrus (ACC) being key drivers of both IBS and its psychiatric comorbidities. This study aimed to investigate the functional connectivity (FC) patterns of pregenual ACC (pgACC) and anterior midcingulate cortex (aMCC) in IBS patients with depressive symptoms (DEP-IBS). A whole-brain FC analysis was conducted using pgACC and aMCC as regions of interest in three groups: 28 DEP-IBS patients, 21 IBS patients without depressive symptoms (nDEP-IBS), and 36 matched healthy controls (HCs). Partial correlation and mediation analyses were performed between abnormal FC and clinical symptoms. The ability of aberrant FC to identify IBS and its psychiatric comorbidity was evaluated using receiver operating characteristic (ROC) curve. DEP-IBS patients exhibited increased pgACC-related FC in the left medial prefrontal cortex (mPFC) and aMCC-related FC in the right middle frontal gyrus, angular gyrus and cerebellum, while showing decreased aMCC-related FC in the right precentral gyrus, superior parietal gyrus and precuneus. Both patient groups demonstrated increased FC between aMCC and left dorsolateral prefrontal cortex (dlPFC), effectively distinguishing them from HCs (AUC = 0.755). The FC between pgACC and left mPFC partially mediated the relationship between gastrointestinal and depressive symptoms, effectively distinguishing DEP-IBS from nDEP-IBS patients (AUC = 0.808). Aberrant FC within the emotional arousal network may serve as a neurobiological marker for IBS with comorbid depression. Furthermore, abnormal FC between the aMCC and the dlPFC may underlie the neural mechanism of IBS.
Collapse
Affiliation(s)
- Ruoyu Tang
- School of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Zhejiang, Hangzhou, China
- Zhejiang Key Laboratory for Research in Assessment of Cognitive Impairments, Hangzhou, Zhejiang, China
| | - Yihan Jin
- School of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Zhejiang, Hangzhou, China
- Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Kuanghui Xu
- School of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Zhejiang, Hangzhou, China
- Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Liqiang Wu
- School of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Zhejiang, Hangzhou, China
- Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Xiaofei Chen
- Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Yun Guo
- Department of Gastroenterology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Guodong Li
- Department of Gastroenterology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Jie Li
- School of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Zhejiang, Hangzhou, China.
- Zhejiang Key Laboratory for Research in Assessment of Cognitive Impairments, Hangzhou, Zhejiang, China.
- Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
| |
Collapse
|
74
|
Zhang R, Li D, Fang H, Xie Q, Tang H, Chen L. Iron-dependent mechanisms in Acinetobacter baumannii: pathogenicity and resistance. JAC Antimicrob Resist 2025; 7:dlaf039. [PMID: 40110557 PMCID: PMC11920509 DOI: 10.1093/jacamr/dlaf039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2025] Open
Abstract
Acinetobacter baumannii is a Gram-negative opportunistic pathogen that poses a significant challenge in healthcare settings, particularly in ICUs, due to its MDR and high mortality rates, especially among critically ill coronavirus disease 2019 patients. Iron is crucial for the survival, growth and pathogenicity of A. baumannii, and the bacterium has developed multiple iron acquisition systems, including siderophore production, haem uptake and TonB-dependent transport mechanisms, to adapt to the iron-limited environment within the host. Although specific studies on A. baumannii are limited, mechanisms from other bacterial species suggest that similar iron acquisition strategies may play a key role in its virulence. Therapeutic approaches targeting these iron-dependent systems, such as the siderophore-conjugated cephalosporin cefiderocol, have shown potential in overcoming MDR A. baumannii infections. Additionally, strategies such as synthetic siderophores, TonB receptor inhibitors and iron chelators are under investigation to enhance treatment outcomes. Future research should prioritize validating these mechanisms in A. baumannii, advancing clinical trials for these therapies and exploring combination treatments to mitigate resistance and improve clinical outcomes in severely affected patients.
Collapse
Affiliation(s)
- Rong Zhang
- Department of Pulmonary and Critical Care Medicine, Southwest Medical University, Luzhou, China
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Dan Li
- Department of Pulmonary and Critical Care Medicine, Southwest Medical University, Luzhou, China
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Hong Fang
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Qian Xie
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Huan Tang
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Lin Chen
- Department of Pulmonary and Critical Care Medicine, Southwest Medical University, Luzhou, China
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
75
|
Gashaw Y, Asmare Z, Tigabie M, Sisay A, Getatachew E, Tadesse S, Bitew G, Ashagre A, Misganaw T, Gashaw M, Kassahun W, Dejazimach Z, Jemal A, Gedfie S, Kumie G, Nigatie M, Abebe W, Kidie AA, Abate BB, Reta MA, Gelaw B. Prevalence of colistin-resistant Enterobacteriaceae isolated from clinical samples in Africa: a systematic review and meta-analysis. BMC Infect Dis 2025; 25:437. [PMID: 40158103 PMCID: PMC11955131 DOI: 10.1186/s12879-025-10826-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Accepted: 03/19/2025] [Indexed: 04/01/2025] Open
Abstract
BACKGROUND Antimicrobial resistance among Enterobacteriaceae poses a significant global threat, particularly in developing countries. Colistin, a critical last-resort treatment for infections caused by carbapenem-resistant and multidrug-resistant strains, is increasingly facing resistance due to inappropriate use of colistin and the spread of plasmid-mediated resistance genes. Despite the significance of this issue, comprehensive and updated data on colistin resistance in Africa is lacking. Thus, the current study was aimed to determine the pooled prevalence of colistin-resistant Enterobacteriaceae in Africa. METHODS A systematic search was conducted across PubMed, Scopus, ScienceDirect, and Google Scholar to identify relevant studies. Forty-one studies reporting on the prevalence of colistin resistance in Enterobacteriaceae isolates from clinical specimens in Africa were included in the analysis. Stata 17 software was used to calculate the pooled prevalence of colistin resistance, employing a random-effects model to determine the event rate of resistance. Heterogeneity across studies was assessed using the I2 statistic, and publication bias was evaluated using Egger's test. Subgroup analyses were performed to address any identified heterogeneity. RESULTS This systematic review analyzed the colistin resistance profile of 9,636 Enterobacteriaceae isolates. The overall pooled prevalence of colistin resistance was 26.74% (95% CI: 16.68-36.80). Subgroup analysis by country revealed significant variability in resistance rates, ranging from 0.5% in Djibouti to 50.95% in South Africa. Species-specific prevalence of colistin resistance was as follows: K. pneumoniae 28.8% (95% CI: 16.64%-41.05%), E. coli 24.5% (95% CI: 11.68%-37.3%), Proteus spp. 50.0% (95% CI: 6.0%-106.03%), and Enterobacter spp. 1.22% (95% CI: -0.5%-3.03%). Analysis based on AST methods revealed significant differences in colistin resistance rates (p = 0.001). The resistance rates varied between 12.60% for the disk diffusion method and 28.0% for the broth microdilution method. Additionally, a subgroup analysis of clinical specimens showed significant variation (p < 0.001) in colistin resistance. Stool specimen isolates had the highest resistance rate at 42.0%, while blood specimen isolates had a much lower resistance rate of 3.58%. CONCLUSIONS Colistin resistance in Enterobacteriaceae is notably high in Africa, with significant variation across countries. This underscores the urgent need for effective antimicrobial stewardship, improved surveillance, and the development of new antibiotics.
Collapse
Affiliation(s)
- Yalewayker Gashaw
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia.
| | - Zelalem Asmare
- Department of Medical Laboratory Science, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia
| | - Mitkie Tigabie
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Asefa Sisay
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Ermias Getatachew
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Selamyhun Tadesse
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Getachew Bitew
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Agenagnew Ashagre
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Tadesse Misganaw
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Muluken Gashaw
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Woldeteklehaymanot Kassahun
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Zelalem Dejazimach
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Abdu Jemal
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Solomon Gedfie
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Getinet Kumie
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Marye Nigatie
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Wagaw Abebe
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Atitegeb Abera Kidie
- Department of Public Health, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Biruk Beletew Abate
- Department of Nursing, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
| | - Melese Abate Reta
- Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O Box 400, Woldia, Ethiopia
- Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Prinshofaq , Pretoria, 0084, South Africa
| | - Baye Gelaw
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| |
Collapse
|
76
|
Zhuang QQ, Lu LY, Lin YL, Yan XL, Chen QQ, Jiang YC, Hong L, Deng HH, Chen W. A Self-Calibrating Chemiluminescence Sensor for Rapid and Precise Antibiotic Prescribing Guidelines on Urinary Tract Infections. ACS Sens 2025; 10:2203-2211. [PMID: 40052751 DOI: 10.1021/acssensors.4c03503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2025]
Abstract
Traditional antimicrobial-susceptibility testing methodologies, including the isolation and culture of bacteria from urine samples and antibiotic-susceptibility test (AST), are expensive and time-consuming. Therefore, a rapid, user-friendly phenotypic AST is urgently needed to guide treatment strategies. Several novel phenotypic AST platforms based on the physiological characteristics of bacteria obtained directly from clinical urine samples have been proposed as promising methods as rapid AST and appropriate antibiotic treatments. However, inaccurate bacterial quantification can lead to false results when high-accuracy quantitative assays are required using these procedures. Coupling the expression of catalase by pathogens with a chemiluminescence-based analytical method enables a convenient and low-cost operation. Herein, we demonstrate a rapid self-calibrating chemiluminescence sensor that can measure bacterial viability through the variation in catalase activity and its response to hydrogen peroxide after treatment with antibiotics. This rapid nanosensor platform can be utilized to determine the antibiotic susceptibility of uropathogenic Escherichia coli and Klebsiella pneumoniae, which account for 80% of all urinary tract infections, directly from clinical urine samples within 40 min without bacterial quantification. The proposed ultrafast and highly accurate AST can enable the precise guidance of antibiotic prescriptions and shorten the time required for clinical decision-making.
Collapse
Affiliation(s)
- Quan-Quan Zhuang
- Quanzhou Clinical Medication Management Quality Control Center, Department of Pharmacy, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
- Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, China
| | - Lin-Yan Lu
- Quanzhou Clinical Medication Management Quality Control Center, Department of Pharmacy, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
- Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, China
| | - Yu-Ling Lin
- Department of Laboratory Medicine, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
| | - Xiao-Li Yan
- Department of Laboratory Medicine, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
| | - Qing-Qing Chen
- Department of Laboratory Medicine, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
| | - Yan-Cheng Jiang
- Department of Laboratory Medicine, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
| | - Lei Hong
- Quanzhou Clinical Medication Management Quality Control Center, Department of Pharmacy, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
| | - Hao-Hua Deng
- Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, China
| | - Wei Chen
- Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, China
| |
Collapse
|
77
|
Yi S, Gao Y, Yu L, Chen Y. Antibacterial sonodynamic nanomedicine: mechanism, category, and applications. BIOMATERIALS TRANSLATIONAL 2025; 6:24-39. [PMID: 40313575 PMCID: PMC12041805 DOI: 10.12336/biomatertransl.2025.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/25/2024] [Revised: 07/08/2024] [Accepted: 03/04/2025] [Indexed: 05/03/2025]
Abstract
Sonodynamic therapy (SDT) has emerged as a cutting-edge strategy for combating multidrug-resistant bacterial infections. Unlike conventional antibiotics, SDT leverages the generation of reactive oxygen species during the treatment process to inflict multifaceted damage on bacterial cells, thereby significantly reducing the likelihood of developing drug resistance. Compared to other physical sterilisation methods, such as ultraviolet irradiation, SDT offers enhanced tissue penetration, making it particularly suitable for addressing deep-seated infections, including osteomyelitis. Despite its significant advantages, the clinical translation of SDT for antibacterial applications faces several challenges. This review discusses the fundamental mechanisms of SDT, with a focus on phenomena such as cavitation-induced reactions and piezocatalytic generation of reactive oxygen species. Furthermore, it provides a comprehensive analysis of various sonosensitisers used in SDT, emphasising their potential to enhance therapeutic outcomes in areas such as infected wound healing, bone regeneration, and the mitigation of deep tissue inflammation. While SDT shows great promise in addressing multidrug-resistant bacterial infections, further research and development are essential to overcome existing limitations and unlock its full clinical potential.
Collapse
Affiliation(s)
- Shuanglong Yi
- Department of Radiology, Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yao Gao
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, China
| | - Luodan Yu
- Department of Radiology, Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yu Chen
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, China
| |
Collapse
|
78
|
Valdez-Martinez A, Santoyo-Alejandre MI, Arenas R, Fuentes-Venado CE, Ramírez-Lozada T, Bastida-González F, Calzada-Mendoza CC, Martínez-Herrera E, Pinto-Almazán R. Neonatal Mucormycosis: A Rare but Highly Lethal Fungal Infection in Term and Preterm Newborns-A 20-Year Systematic Review. Trop Med Infect Dis 2025; 10:86. [PMID: 40278759 PMCID: PMC12030780 DOI: 10.3390/tropicalmed10040086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2025] [Revised: 03/08/2025] [Accepted: 03/13/2025] [Indexed: 04/26/2025] Open
Abstract
BACKGROUND/OBJECTIVES Mucormycosis is a rare but life-threatening fungal infection, particularly in neonates, due to their undeveloped immune system. This systematic review aims to analyze the risk factors, clinical presentations, treatments, and outcomes of neonatal mucormycosis reported between 2004 and 2024. METHODS A systematic literature search was conducted in PubMed, Scopus, and Web of Science following PRISMA guidelines. Only studies reporting cases of mucormycosis in neonates (≤28 days old) were included. Data on risk factors, clinical features, diagnostic methods, antifungal therapies, surgical interventions, and outcomes were extracted and analyzed. RESULTS A total of 44 studies met the inclusion criteria, comprising 61 neonatal cases. The most common clinical presentations were gastrointestinal (n = 39), cutaneous (n = 19), rhino-orbito-cerebral (n = 2), and disseminated mucormycosis (n = 1). Diagnosis was primarily based on histopathology (93.4%) and fungal culture (26.2%). The main antifungal treatment was liposomal amphotericin B (63.9%), often combined with surgical debridement (60.6%). Mortality rates remained high (47.5%), particularly in cases of prematurely extreme neonates with angioinvasive disease or delayed diagnosis. CONCLUSIONS Neonatal mucormycosis remains a severe condition with high morbidity and mortality. Early diagnosis through a combination of clinical suspicion and laboratory confirmation, along with prompt antifungal therapy and surgical management, apparently is crucial for improving outcomes. Further studies are needed to optimize treatment strategies and improve neonatal survival.
Collapse
Affiliation(s)
- Alfredo Valdez-Martinez
- Sección de Micología, Hospital General “Dr. Manuel Gea González”, Tlalpan, Mexico City 14080, Mexico; (A.V.-M.); (R.A.)
- Hospital General del Zona 33, Instituto Mexicano del Seguro Social, Nayarit 63735, Mexico;
| | | | - Roberto Arenas
- Sección de Micología, Hospital General “Dr. Manuel Gea González”, Tlalpan, Mexico City 14080, Mexico; (A.V.-M.); (R.A.)
| | - Claudia Erika Fuentes-Venado
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Mexico City 11340, Mexico; (C.E.F.-V.); (C.C.C.-M.)
- Servicio de Medicina Física y Rehabilitación, Hospital General de Zona No 197, Texcoco 56160, Mexico
| | - Tito Ramírez-Lozada
- Servicio de Ginecología y Obstetricia, Hospital Regional de Alta Especialidad de Ixtapaluca, Instituto Mexicano de Seguro Social para el Bienestar (IMSS-BIENESTAR), Carretera Federal México-Puebla Km 34.5, Ixtapaluca 56530, Mexico;
| | - Fernando Bastida-González
- Laboratorio de Biología Molecular, Laboratorio Estatal de Salud Pública del Estado de México, Toluca de Lerdo 50130, Mexico;
| | - Claudia Camelia Calzada-Mendoza
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Mexico City 11340, Mexico; (C.E.F.-V.); (C.C.C.-M.)
| | - Erick Martínez-Herrera
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Mexico City 11340, Mexico; (C.E.F.-V.); (C.C.C.-M.)
- Fundación Vithas, Grupo Hospitalario Vithas, 28043 Madrid, Spain
- Efficiency, Quality, and Costs in Health Services Research Group (EFISALUD), Galicia Sur Health Research Institute (IISGS), Servizo Galego de Saúde-Universidade de Vigo (UVIGO), 36213 Vigo, Spain
| | - Rodolfo Pinto-Almazán
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Mexico City 11340, Mexico; (C.E.F.-V.); (C.C.C.-M.)
- Fundación Vithas, Grupo Hospitalario Vithas, 28043 Madrid, Spain
| |
Collapse
|
79
|
Volkan E, Karanis P. Current Risks and Prevention Strategies Against Vector-Borne Diseases in Cyprus. Microorganisms 2025; 13:726. [PMID: 40284563 PMCID: PMC12029801 DOI: 10.3390/microorganisms13040726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 03/20/2025] [Accepted: 03/21/2025] [Indexed: 04/29/2025] Open
Abstract
The island of Cyprus has historically been prone to vector-borne diseases due to its location at the crossroads of three continents. The introduction of novel vectors, microorganisms, or strains in Cyprus, coupled with the global climate change and antimicrobial resistance crisis, can lead to an altered infectious disease landscape and entomological status, causing a rise in vector-borne diseases on the island. The current review provides a broad snapshot of the status of vector-borne infectious diseases and associated risks in Cyprus. Our research has uncovered a pressing issue, the risk of the spread and emergence of various infectious diseases, including West Nile virus and malaria, respectively, due to the presence of Aedes and Anopheles spp. mosquitoes on the island, while underscoring the animal reservoirs of several pathogenic microorganisms. Our research emphasizes the importance of the One Health approach and the collaboration between communities for the improvement of vector control strategies to limit the spread of vector borne diseases.
Collapse
Affiliation(s)
- Ender Volkan
- Department of Basic and Clinical Sciences, University of Nicosia Medical School, 2414 Nicosia, Cyprus
| | - Panagiotis Karanis
- Department of Basic and Clinical Sciences, University of Nicosia Medical School, 2414 Nicosia, Cyprus
| |
Collapse
|
80
|
Alves FS, Sousa AP, Almeida-Júnior A, Lima PSV, Silva MFR, Galvão JLFM, Lima EO, Souza HDS, Luis JAS, Athayde-Filho PF, Fiss GF. Antimicrobial Investigation of Phthalimide and N-Phthaloylglycine Esters: Activity, Mechanism of Action, Synergism and Ecotoxicity. Life (Basel) 2025; 15:518. [PMID: 40283073 PMCID: PMC12028801 DOI: 10.3390/life15040518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2025] [Revised: 03/18/2025] [Accepted: 03/19/2025] [Indexed: 04/29/2025] Open
Abstract
Motivated by the search for novel antimicrobials against opportunistic resistant pathogens and based on the reported antimicrobial activity of phthalimides, two series of phthalimide and N-phthaloylglycine esters were designed to investigate whether the addition of butyl and aryl groups enhances their antimicrobial properties. Thus, in vitro antimicrobial activity, antifungal mechanism of action, effect combined with Chloramphenicol, in silico/vitro toxicity, and a docking molecular were studied. Phthalimide and N-phthaloylglycine aryl esters were obtained in yields of 75-98%. Phthalimide aryl ester 3b (R = Me) showed the best results against Gram-(+) and Gram-(-) bacteria, S. aureus and P. aeruginosa, respectively, and yeast fungi, C. tropicalis and C. albicans, with MIC values equal to 128 µg·mL-1. Regarding the antifungal mechanism of action on C. albicans, the MIC values of compound 3b changed from 128 to 1024 µg·mL-1 in the presence of ergosterol. Furthermore, compound 3b showed synergy with Chloramphenicol against P. aeruginosa, with a FICI value equal to 0.5. Finally, the four most promising compounds had their in silico/vitro toxicity evaluated, which showed moderate toxicity to non-toxicity on Artemia salina larvae. With the exception of Chloramphenicol, all selected compounds, including Fluconazole, are potentially hepatotoxic, but they were predicted not to cause skin sensitization, suggesting a potential application for topical use. Molecular docking revealed that compound 3b exhibits superior binding affinity and stability with the 50S ribosomal subunit (-92.69 kcal·mol-1) compared to Chloramphenicol, and a unique π-sulfur interaction with CYP51, suggesting its potential as a dual-action antibacterial and antifungal candidate against resistant pathogens.
Collapse
Affiliation(s)
- Francinara S. Alves
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| | - Abraão P. Sousa
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| | - Alexandre Almeida-Júnior
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| | - Priscila S. V. Lima
- Núcleo de Química de Heterociclos (NUQUIMHE), Department of Chemistry, Federal University of Santa Maria, Santa Maria 97105-900, Brazil;
| | - Marcelo F. R. Silva
- Laboratório Multiusuário de Caracterização e Análises (LMCA), Institute of Research in Drugs and Medicines, Federal University of Paraíba, João Pessoa 58051-900, Brazil;
| | - José L. F. M. Galvão
- Nova Esperança University Hospital, Nova Esperança College, João Pessoa 58067-695, Brazil;
| | - Edeltrudes O. Lima
- Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Brazil;
| | - Helivaldo D. S. Souza
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| | - José A. S. Luis
- Center of Education and Health, Federal University of Campina Grande, Cuité 58429-600, Brazil;
| | - Petrônio F. Athayde-Filho
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| | - Gabriela F. Fiss
- Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS), Department of Chemistry, Federal University of Paraíba, João Pessoa 58051-900, Brazil; (F.S.A.); (A.P.S.); (A.A.-J.); (H.D.S.S.); (P.F.A.-F.)
| |
Collapse
|
81
|
Jameel S, Khan MA, Asif A, Hameed H, Ur Rahman S, Irfan A, Shazly GA, Bin Jardan YA. Exploring the antibacterial efficacy of Opuntia monacantha in combatting methicillin-resistant Staphylococcus aureus. Sci Rep 2025; 15:9552. [PMID: 40108249 PMCID: PMC11923071 DOI: 10.1038/s41598-025-93939-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Accepted: 03/10/2025] [Indexed: 03/22/2025] Open
Abstract
Public health is seriously threatened by the rise of antibiotic-resistant strains of bacteria, especially methicillin resistant Staphylococcus aureus (MRSA). This study investigated the phytochemical compounds, and possible antibacterial effects of a methanolic extract of the cactus species Opuntia monacantha Haw. against MRSA. The powdered substance was extracted with methanol and filtered, and the filtrate was partitioned with n-hexane, chloroform and ethyl acetate. The fractions with higher percentage yields such as the n-hexane and chloroform fractions went through GC-MS analysis. They consist of various compounds that are known to have strong antioxidant and antimicrobial activities. The antimicrobial activity of the plant was measured via a diffusion assay. On the basis of these results, the Opuntia monacantha crude methanolic extract, and the n-hexane and chloroform fractions significantly inhibited all the MRSA strains used in the test at 100, 75 and 50 mg/mL. Furthermore, the minimum inhibitory concentrations of various fractions of the methanolic extract of Opuntia monacantha were also examined. Therefore, Opuntia could be a promising candidate for strengthening the existing formulations in pharmaceutical science for the treatment of MRSA. However, additional research is necessary before its therapeutic use is recommended. The results are intended to provide important new information for the creation of sustainable and alternative antimicrobial agents.
Collapse
Affiliation(s)
- Sana Jameel
- Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, Pakistan
| | - Mahtab Ahmad Khan
- Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, Pakistan.
- Institute of Clinical and Experimental Pharmacology & Toxicology, University of Lübeck, Lübeck, Germany.
| | - Ayesha Asif
- Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, Pakistan
| | - Huma Hameed
- Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, Pakistan
| | - Shafeeq Ur Rahman
- Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, Pakistan
| | - Ali Irfan
- Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan.
| | - Gamal A Shazly
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Yousef A Bin Jardan
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
| |
Collapse
|
82
|
Allegranzi B, Tartari E, Kilpatrick C, Storr J, Bellare N, Bana J, Flávia Santos A, Charnaud S, Ross AL, Schwaber MJ, Pittet D. WHO global research agenda for hand hygiene improvement in health care: a Delphi consensus study. Infect Control Hosp Epidemiol 2025; 46:1-16. [PMID: 40109269 PMCID: PMC7617569 DOI: 10.1017/ice.2025.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2025]
Abstract
OBJECTIVE To identify global research priorities for improving hand hygiene in healthcare settings and develop a 2023-2030 research agenda to guide funding, coordinate research, promote investment, and inform policy for enhanced healthcare quality and safety. DESIGN Expert consensus study using a modified Delphi process. PARTICIPANTS A 105-member panel of international hand hygiene experts including the World Health Organization (WHO) Technical Advisory Group of Experts on Hand Hygiene in Healthcare representing all WHO regions and World Bank income levels. METHODS The research priorities were identified through a multiphase approach including a meta-review to establish knowledge gaps and inform initial priorities, followed by expert consultations using a modified Delphi process. 192 preliminary priorities were included in a two-round Delphi survey. Experts rated each priority in the first round, and then reviewed and adjusted responses based on the panel's aggregated, anonymous responses in the second round. Ratings were collected on a five-point Likert scale. Consensus was defined as a combined "strongly agree" and "agree" frequency of at least 70%. RESULTS Consensus was achieved for 178 of 192 priorities (92.7%), categorized into six domains: system change; training and education; evaluation and feedback; reminders and communications; institutional safety climate; and hand hygiene improvement impact on healthcare-associated infections and antimicrobial resistance. Of these, 121 priorities reached >80% consensus. The Delphi process, maintained a 92% response rate over two rounds. CONCLUSIONS A structured consensus process yielded a research agenda to address gaps in hand hygiene improvement, supporting enhanced healthcare quality and safety globally.
Collapse
Affiliation(s)
- Benedetta Allegranzi
- Infection Prevention and Control Unit and Hub, Department of Integrated Health Services, World Health Organization, Geneva, Switzerland
| | - Ermira Tartari
- Infection Prevention and Control Unit and Hub, Department of Integrated Health Services, World Health Organization, Geneva, Switzerland
- Faculty of Health Sciences, University of Malta, Msida, Malta
| | - Claire Kilpatrick
- Infection Prevention and Control Unit and Hub, Department of Integrated Health Services, World Health Organization, Geneva, Switzerland
| | - Julie Storr
- Infection Prevention and Control Unit and Hub, Department of Integrated Health Services, World Health Organization, Geneva, Switzerland
| | - Nita Bellare
- Infection Prevention and Control Unit and Hub, Department of Integrated Health Services, World Health Organization, Geneva, Switzerland
| | | | - Ana Flávia Santos
- CEGIST, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - Sarah Charnaud
- Research for Health department, World Health Organization, Geneva, Switzerland
| | - Anna Laura Ross
- Research for Health department, World Health Organization, Geneva, Switzerland
| | - Mitchell J. Schwaber
- National Center for Infection Control, Israel Ministry of Health, Jerusalem, Israel
| | - Didier Pittet
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
| |
Collapse
|
83
|
Kaur N, Kumar P, Dhami M, Aran KR. Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health. Mol Biol Rep 2025; 52:319. [PMID: 40095156 DOI: 10.1007/s11033-025-10425-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2025] [Accepted: 03/10/2025] [Indexed: 03/19/2025]
Abstract
Cardiovascular diseases (CVDs) remain the major cause of morbidity and mortality amongst people of all ages across the world. Research suggests that the initiation and progression of CVDs are associated with antibiotic-induced gut dysbiosis. Antibiotics are primarily intended to be used to treat bacterial infections, which can alter gut microbiota (GM) composition, by lowering the abundance of beneficial bacteria, like Firmicutes, Bacteroidetes, and increasing the profusion of Enterobacteriaceae, leading to harm on gut health. Additionally, it reduces short-chain fatty acids (SCFAs) and bile acid metabolism, increases trimethylamine N-oxide (TMAO) production, intestinal permeability allowing lipopolysaccharide (LPS) and TMAO into systemic circulation. SCFAs play a key role in lipid metabolism, inflammation, and strengthening of the intestinal barrier, and participate in CVDs through FFAR2 and FFAR3 receptors, whereas dysbiosis reduces SCFAs levels and worsens these effects. TMAO enhances oxidative stress, inflammation, endothelial dysfunction, and cholesterol dysregulation, thus worsening CVDs. Furthermore, LPS develops systemic inflammation, insulin resistance, and endothelial dysfunction by activating the NF-κB pathway. Dysbiosis also affects bile acid synthesis, disrupting lipid and glucose metabolism, further participating in the progression of CVDs. This article aims to explore the role of gut dysbiosis in various CVDs, including congenital heart disease, hypertension, valvular heart disease, coronary heart disease, and heart failure. Furthermore, this article aims to bridge the knowledge gap regarding the gut-heart axis by exploring how antibiotics alter the gut microbiota homeostasis, further contributing to the development of CVDs and therapeutic interventions that reduce cardiovascular risks and restore the gut microbiota homeostasis.
Collapse
Affiliation(s)
- Navpreet Kaur
- Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, India
| | - Pankaj Kumar
- Department of Pharmacology, Himachal Institute of Pharmaceutical Education and Research (HIPER), Tehsil-Nadaun, Hamirpur, Himachal Pradesh, 177033, India
| | - Mahadev Dhami
- Bhimdatta Polytechnic Institute, Patan, Baitadi, 10200, Nepal
| | - Khadga Raj Aran
- Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
| |
Collapse
|
84
|
Geremia N, Marino A, De Vito A, Giovagnorio F, Stracquadanio S, Colpani A, Di Bella S, Madeddu G, Parisi SG, Stefani S, Nunnari G. Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options. Antibiotics (Basel) 2025; 14:306. [PMID: 40149115 PMCID: PMC11939765 DOI: 10.3390/antibiotics14030306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2025] [Revised: 03/12/2025] [Accepted: 03/14/2025] [Indexed: 03/29/2025] Open
Abstract
Non-fermenting Gram-negative bacteria (NFGNB) are a heterogeneous group of opportunistic pathogens increasingly associated with healthcare-associated infections. While Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia are well known, rarer species such as Burkholderia cepacia complex, Achromobacter spp., Chryseobacterium spp., Elizabethkingia spp., Ralstonia spp., and others pose emerging therapeutic challenges. Their intrinsic and acquired resistance mechanisms limit effective treatment options, making targeted therapy essential. Objectives: This narrative review summarizes the current understanding of rare and unusual NFGNB, their clinical significance, resistance profiles, and evidence-based therapeutic strategies. Methods: A literature review was conducted using PubMed, Scopus, and Web of Science to identify relevant studies on the epidemiology, antimicrobial resistance, and treatment approaches to rare NFGNB. Results: Rare NFGNB exhibits diverse resistance mechanisms, including β-lactamase production, efflux pumps, and porin modifications. Treatment selection depends on species-specific susceptibility patterns, but some cornerstones can be individuated. Novel β-lactam/β-lactamase inhibitors and combination therapy approaches are being explored for multidrug-resistant isolates. However, clinical data remain limited. Conclusions: The increasing incidence of rare NFGNB requires heightened awareness and a tailored therapeutic approach. Given the paucity of clinical guidelines, antimicrobial stewardship and susceptibility-guided treatment are crucial in optimizing patient outcomes.
Collapse
Affiliation(s)
- Nicholas Geremia
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale “dell’Angelo”, 30174 Venice, Italy;
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Civile “S.S. Giovanni e Paolo”, 30122 Venice, Italy
| | - Andrea Marino
- Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy;
| | - Andrea De Vito
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy; (A.D.V.); (A.C.); (G.M.)
| | - Federico Giovagnorio
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy; (F.G.); (S.G.P.)
| | - Stefano Stracquadanio
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; (S.S.); (S.S.)
| | - Agnese Colpani
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy; (A.D.V.); (A.C.); (G.M.)
| | - Stefano Di Bella
- Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34129 Trieste, Italy;
| | - Giordano Madeddu
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy; (A.D.V.); (A.C.); (G.M.)
| | | | - Stefania Stefani
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; (S.S.); (S.S.)
| | - Giuseppe Nunnari
- Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy;
| |
Collapse
|
85
|
Gentile I, Scotto R, Scirocco MM, Di Brizzi F, Cuccurullo F, Silvitelli M, Ametrano L, Alfè FA, Pietroluongo D, Irace I, Chiariello M, De Felice N, Severino S, Viceconte G, Schiano Moriello N, Maraolo AE, Buonomo AR, Giaccone A, on behalf of Federico II COVID Team. Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case-Control Study (SAVALO Study). Microorganisms 2025; 13:669. [PMID: 40142561 PMCID: PMC11944734 DOI: 10.3390/microorganisms13030669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2025] [Revised: 03/04/2025] [Accepted: 03/09/2025] [Indexed: 03/28/2025] Open
Abstract
We conducted a real-life case-control study among outpatients with Omicron SARS-CoV-2 infection to assess the effectiveness of molnupiravir (MNP) in reducing hospital admission, admission to the intensive care unit, and death at day 28. Cases were SARS-CoV-2-positive patients seeking medical care within five days of symptom onset from 1 January to 31 December 2022, who received MNP. Controls were selected from a regional database among positive subjects who did not receive antiviral treatment for SARS-CoV-2. A total of 1382 patients were included (146 cases, 1236 controls). Vaccinated patients had a lower risk of mortality and of the composite outcome (hospital admission, ICU admission, or all-cause death) than unvaccinated ones (0.6% vs. 7.8%, p < 0.001 and 2% vs. 7.8%, p = 0.001, respectively). After full-matching propensity score analysis, MNP-treated subjects had a lower incidence of the composite outcome, although no effect was observed on individual outcomes. In subgroup analyses by vaccination status, MNP was effective in preventing all outcomes among unvaccinated patients and reduced the risk of ICU admission in both vaccinated and unvaccinated patients. Molnupiravir treatment effectively reduced the composite outcome risk in outpatients with SARS-CoV-2 infection, with a more pronounced benefit in unvaccinated patients. These findings highlight MNP's potential to help prevent disease progression in high-risk patients, thereby supporting its role as an outpatient therapeutic option for COVID-19.
Collapse
Affiliation(s)
- Ivan Gentile
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Riccardo Scotto
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Maria Michela Scirocco
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Francesco Di Brizzi
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Federica Cuccurullo
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Maria Silvitelli
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Luigi Ametrano
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Francesco Antimo Alfè
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Daria Pietroluongo
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Irene Irace
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Mariarosaria Chiariello
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Noemi De Felice
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Simone Severino
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Giulio Viceconte
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Nicola Schiano Moriello
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Alberto Enrico Maraolo
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Antonio Riccardo Buonomo
- Department of Clinical Medicine and Surgery—Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy; (I.G.); (M.M.S.); (F.D.B.); (F.C.); (M.S.); (L.A.); (F.A.A.); (D.P.); (I.I.); (M.C.); (N.D.F.); (S.S.); (G.V.); (N.S.M.); (A.E.M.); (A.R.B.)
| | - Agnese Giaccone
- Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, AORN Ospedali dei Colli, Cotugno Hospital, 80131 Naples, Italy;
| | | |
Collapse
|
86
|
Sabawoon A, Naderi S, Sadaat SI, Rasheed A, Atarud A, Tavakoli F, Sahrifi H, Mirzazadeh A. Recent HIV testing and self-reported HIV prevalence among men who inject drugs in Afghanistan: a nationwide survey in 2019-2020. Harm Reduct J 2025; 22:31. [PMID: 40087689 PMCID: PMC11907865 DOI: 10.1186/s12954-025-01183-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2024] [Accepted: 02/26/2025] [Indexed: 03/17/2025] Open
Abstract
BACKGROUND People who inject drugs (PWID) remain at high risk for HIV in many countries, including Afghanistan. Previous reports on HIV testing and prevalence in Afghanistan were published in 2012. This study assessed recent HIV testing and self-reported HIV prevalence among male PWID in Afghanistan from 2019 to 2020. METHOD We visited 374 public venues and hotpots where PWID used to gather and meet their peers across 8 cities in Afghanistan to enroll eligible participants in our study. Using interviews and a survey, our trained interviewers collected data on the demographics, types of drugs, HIV testing history, and self-reported HIV status of the participants. We analyzed the data using the venues and hotpots as clusters to report the percentages of recent HIV tests and self-reported HIV prevalence overall and in subgroups defined by demographic characteristics and locations. RESULTS Among the 1385 participants, most were from Kabul city (28.9%), spoke Dari (67.4%), were aged 25-34 years (42.1%), and were married (52.4%). Overall, 70.7% (95% CI 67.6-73.6) (ranging from 20.0% in Kandahar to 99.3% in Mazar-i-Sharif) were tested for HIV within the past 12 months. Among those who had ever been tested for HIV, 20.7% (95% CI 17.8-24.0) (ranging from 0% in Zarang to 63.2% in Kabul) reported being positive for HIV. CONCLUSION Compared with the results of a similar study in 2012, we found a significant improvement in HIV testing coverage among PWID in Afghanistan. The high self-reported HIV prevalence among this group also highlights the need for targeted screening and treatment programs for PWID in Afghanistan, particularly in the cities of Kabul and Jalalabad.
Collapse
Affiliation(s)
- Ajmal Sabawoon
- Kabul Medical University, Kabul, Afghanistan
- Mailman School of Public Health, Columbia University, New York City, NY, USA
| | - Sima Naderi
- Institute for Global Health Sciences, University of California, San Francisco, CA, USA
| | - Said Iftekhar Sadaat
- Institute for Global Health Sciences, University of California, San Francisco, CA, USA
| | - Abdul Rasheed
- Health Commons Solutions Lab, Toronto, ON, Canada
- Youth Health and Development Organization, Kabul, Afghanistan
| | - Alim Atarud
- Independent Global Health Consult, Kabul, Afghanistan
| | - Fatemeh Tavakoli
- HIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran
| | - Hamid Sahrifi
- HIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran
| | - Ali Mirzazadeh
- Institute for Global Health Sciences, University of California, San Francisco, CA, USA.
| |
Collapse
|
87
|
Pagano L, Fernández OM. Clinical aspects and recent advances in fungal diseases impacting human health. J Antimicrob Chemother 2025; 80:i2-i8. [PMID: 40085539 PMCID: PMC11908536 DOI: 10.1093/jac/dkaf004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Accepted: 12/04/2024] [Indexed: 03/16/2025] Open
Abstract
Fungal diseases are of growing clinical concern in human medicine as the result of changes in the epidemiology, diversity in clinical presentation, emergence of new pathogens, difficulties in diagnosis and increasing resistance to antifungals of current available classes. There is a need for high disease awareness among the public and healthcare physicians, improvement in diagnostic methods and the development of drugs from new therapeutic classes with an improved resistance profile. In this article, we will explore some key aspects of fungal diseases in humans and provide a general overview of this important topic.
Collapse
Affiliation(s)
- Livio Pagano
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy
- Fondazione Policlinico Universitario Agostino Gemelli – IRCCS, Rome, Italy
| | | |
Collapse
|
88
|
Karimian P, Akbari M, Shirzadi M, Safiri S, Alnaseri M, Karimi N, Aboutalebi MS, Dezfouli M, Solgi H. Knowledge, attitudes, and practices of ICU head nurses regarding infection control and antimicrobial resistance in Iran: a cross-sectional study. BMC Nurs 2025; 24:278. [PMID: 40075396 PMCID: PMC11905550 DOI: 10.1186/s12912-025-02937-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Accepted: 03/06/2025] [Indexed: 03/14/2025] Open
Abstract
BACKGROUND In the intensive care unit (ICU), infections due to multidrug-resistant (MDR) bacteria lead to poor clinical outcomes, prolonged ICU and hospital stays, high mortality and morbidity rates, and higher patient care cost. This study investigated knowledge, attitudes and practices (KAP) of ICU head nurses in Iran towards infection prevention and control (IPC) measures and antimicrobial resistance (AMR). METHODS This study was conducted among 61 ICU head nurses of the 36 hospitals in Isfahan, Iran on 19th July 2023. Data was collected by self-administer questionnaires. Data analysis was performed using SPSS version 25.0 level of significance was considered to be less than 0.05 in all tests. RESULTS Of the 61 participants, 56 (91.8%) were female and their ages ranged from 27 to 56 years old with a mean age of 39.3 ± 5.6 years. 75.4% of participants had a bachelor's degree and 24.6% had a master's degree. The mean work experience in the ICU and duration of experience in the hospital was 8.1 and 16.2 years, respectively. The mean scores for KAP were 3.84 ± 1.86 (with a range of 0-9), 55.00 ± 12.50, 35.84 ± 4.19 (with a range of 24-48) and 21.27 ± 3.13 (with a range of 17-29), respectively. There was a significant relationship between knowledge and total years of experience (r = 0.256, P < 0.048). CONCLUSION The study showed that most participants had weak knowledge, a positive attitude and weak practices. Consequently, more emphasis is needed to improve the ICU head nurses' KAP toward IPC measures and AMR, especially in areas where gaps were identified. Additionally, there is a need to an educational plan on these topics in the training of nursing programs.
Collapse
Affiliation(s)
- Parisa Karimian
- Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mojtaba Akbari
- Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Shirzadi
- Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Simin Safiri
- Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Maliheh Alnaseri
- Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Narjes Karimi
- Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Sadegh Aboutalebi
- Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Majid Dezfouli
- Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Hamid Solgi
- Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Amin Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
| |
Collapse
|
89
|
Mudenda S, Kapolowe K, Chirwa U, Chanda M, Chanda R, Kalaba R, Fwoloshi S, Phiri C, Mwamba M, Chirwa RK, Nikoi K, Musonda L, Yamba K, Chizimu JY, Chanda C, Mubanga T, Simutowe C, Kasanga J, Mukanwa M, Mutengo KH, Matthew P, Arnedo FM, Joshi J, Mayito J, Nakazwe R, Kasanga M, Chanda D. Antimicrobial Stewardship Impact on Antibiotic Use in Three Tertiary Hospitals in Zambia: A Comparative Point Prevalence Survey. Antibiotics (Basel) 2025; 14:284. [PMID: 40149095 PMCID: PMC11939251 DOI: 10.3390/antibiotics14030284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2025] [Revised: 02/02/2025] [Accepted: 02/07/2025] [Indexed: 03/29/2025] Open
Abstract
Introduction: Antimicrobial stewardship (AMS) can improve the rational use of antibiotics in hospitals. This study assessed the impact of a multifaceted AMS intervention on antibiotic use and prescribing patterns at three tertiary hospitals in Zambia. Methods: Point Prevalence Surveys (PPS) were conducted in three tertiary hospitals in August 2022 and in October 2023. It was part of a 3-year AMS demonstration project that aimed to optimize the use of antibiotics in treating urinary tract infections (UTIs) and bloodstream infections (BSIs) in various health sector settings in Zambia. Up to 170 medical records in 2022 and 265 in 2023 were included in the assessment. Results: Overall, the prevalence of antibiotic use in this PPS was 75%. Eighty-one percent (81%) and 71% of patients assessed were on at least one antibiotic in 2022 and 2023, respectively, indicating a decrease of 10%. Similarly, prescribing ceftriaxone, the most prescribed antibiotic, declined from an average of 48% in 2022 to 38% in 2023. Adherence to Standard Treatment Guidelines (STGs) slightly increased from 42% in 2022 to 45% in 2023. Additionally, antibiotic prescribing was reduced from 1.38 to 1.21. Conclusions: Antimicrobial stewardship had an early positive impact on antibiotic use and adherence to Standard Treatment Guidelines.
Collapse
Affiliation(s)
- Steward Mudenda
- Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka 10101, Zambia
| | - Kenneth Kapolowe
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Uchizi Chirwa
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Melvin Chanda
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Raphael Chanda
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Rodney Kalaba
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Sombo Fwoloshi
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Christabel Phiri
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Mukuka Mwamba
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Robert Kajaba Chirwa
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Kotey Nikoi
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Linda Musonda
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Kaunda Yamba
- Antimicrobial Resistance Coordinating Committee, Zambia National Public Health Institute, Lusaka 10101, Zambia; (K.Y.); (J.Y.C.)
| | - Josepsh Yamweka Chizimu
- Antimicrobial Resistance Coordinating Committee, Zambia National Public Health Institute, Lusaka 10101, Zambia; (K.Y.); (J.Y.C.)
| | - Chitalu Chanda
- Ndola Teaching Hospital, Ndola 10101, Zambia; (C.C.); (T.M.); (C.S.)
| | - Tamica Mubanga
- Ndola Teaching Hospital, Ndola 10101, Zambia; (C.C.); (T.M.); (C.S.)
| | - Chisha Simutowe
- Ndola Teaching Hospital, Ndola 10101, Zambia; (C.C.); (T.M.); (C.S.)
| | - John Kasanga
- Livingstone University Teaching Hospital, Livingstone 10101, Zambia; (J.K.); (M.M.); (K.H.M.)
| | - Mulope Mukanwa
- Livingstone University Teaching Hospital, Livingstone 10101, Zambia; (J.K.); (M.M.); (K.H.M.)
| | - Katongo Hope Mutengo
- Livingstone University Teaching Hospital, Livingstone 10101, Zambia; (J.K.); (M.M.); (K.H.M.)
| | - Philip Matthew
- International Center for Antimicrobial Resistance Solutions (ICARS), Ørestads Boulevard 5, 2300 Copenhagen, Denmark; (P.M.); (F.M.A.); (J.J.); (J.M.)
| | - Fabian Maza Arnedo
- International Center for Antimicrobial Resistance Solutions (ICARS), Ørestads Boulevard 5, 2300 Copenhagen, Denmark; (P.M.); (F.M.A.); (J.J.); (J.M.)
| | - Jyoti Joshi
- International Center for Antimicrobial Resistance Solutions (ICARS), Ørestads Boulevard 5, 2300 Copenhagen, Denmark; (P.M.); (F.M.A.); (J.J.); (J.M.)
| | - Jonathan Mayito
- International Center for Antimicrobial Resistance Solutions (ICARS), Ørestads Boulevard 5, 2300 Copenhagen, Denmark; (P.M.); (F.M.A.); (J.J.); (J.M.)
| | - Ruth Nakazwe
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| | - Maisa Kasanga
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
- Department of Epidemiology and Biostatistics, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
| | - Duncan Chanda
- University Teaching Hospitals, Lusaka 10101, Zambia; (K.K.); (U.C.); (M.C.); (R.C.); (R.K.); (S.F.); (C.P.); (M.M.); (R.K.C.); (K.N.); (L.M.); (R.N.); (M.K.)
| |
Collapse
|
90
|
Rawson TM, Moore LS, Lamorde M. Addressing the challenge of antimicrobial resistance. COMMUNICATIONS MEDICINE 2025; 5:67. [PMID: 40050472 PMCID: PMC11885620 DOI: 10.1038/s43856-025-00758-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2025] Open
Affiliation(s)
- Timothy M Rawson
- Centres for Antimicrobial Optimisation Network, Imperial College London, London, UK.
- Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
- The David Price Evans Global Health & Infectious Diseases Group, The University of Liverpool, Liverpool, UK.
| | - Luke Sp Moore
- Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK
- Clinical Infection Department, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
| | - Mohammed Lamorde
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
| |
Collapse
|
91
|
Cotugno S, De Vita E, Frallonardo L, Novara R, Papagni R, Asaduzzaman M, Segala FV, Veronese N, Nicastri E, Morea A, Farkas FB, Lakatos B, Iatta R, Putoto G, Saracino A, Di Gennaro F. Antimicrobial Resistance and Migration: Interrelation Between Two Hot Topics in Global Health. Ann Glob Health 2025; 91:12. [PMID: 40061583 PMCID: PMC11887466 DOI: 10.5334/aogh.4628] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2024] [Accepted: 02/01/2025] [Indexed: 05/13/2025] Open
Abstract
Background: Antimicrobial resistance (AMR) and migration are two interlinked issues and both pose an escalating threat to global health. With an increasing trend, there are 281 million migrants globally, while AMR is contributing to over 5 million deaths annually, with a projected rise to 10 million by 2050 if left unaddressed. Both AMR and migration are multifaceted problems that extend beyond human health, involving animals, plants, and the environment-a fact highlighted by the One Health approach. Objective: The aim of this work is: (1) to examine the complex relationship between migration and AMR, drawing on epidemiological data, surveillance strategies, and healthcare access challenges and (2) to address an interventional strategy proposal. Methods: We performed a narrative review of the most updated literature about migration and AMR using three primary databases: PubMed, Scopus, and Embase. Findings: Migrants, particularly from low‑ and middle‑income countries, represent a unique group at increased risk of AMR due to factors such as overcrowded living conditions, limited access to healthcare, uncontrolled use of antibiotics, and high prevalence of AMR in origin countries. Studies reveal higher rates of AMR colonization and infection among migrants compared with native populations, with specific pathogens such as MRSA and multidrug‑resistant gram‑negative bacteria posing significant risks. Migratory conditions, socioeconomic vulnerability, and healthcare barriers contribute to this heightened risk. Conclusion: To address the intersection of migration and AMR, interventions must focus on improving living conditions, enhancing healthcare access, promoting appropriate antibiotic use, and strengthening microbiological surveillance. Multisectoral collaboration is essential to mitigate the spread of AMR and safeguard both migrant and global public health.
Collapse
Affiliation(s)
- Sergio Cotugno
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Elda De Vita
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Luisa Frallonardo
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Roberta Novara
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Roberta Papagni
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Muhammad Asaduzzaman
- Department of Community Medicine and Global Health, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Francesco Vladimiro Segala
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Nicola Veronese
- Saint Camillus International University of Health Sciences, Rome, Italy
| | - Emanuele Nicastri
- Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, 00149, Rome, Italy
| | - Anna Morea
- Interdisciplinary Department of Medicine, University of Bari, Bari, Italy
| | - Ferenc Balázs Farkas
- Institute of Medical Microbiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary; Pediatric Center, Semmelweis University, Budapest, Hungary
| | - Botond Lakatos
- Semmelweis University Department of Internal Medicine and Hematology, Departmental Group of Infectious Diseases, Budapest, Hungary
| | - Roberta Iatta
- Interdisciplinary Department of Medicine, University of Bari, Bari, Italy
| | - Giovanni Putoto
- Operational Research Unit, Doctors with Africa CUAMM, Padova, Italy
| | - Annalisa Saracino
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| | - Francesco Di Gennaro
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‑J), Unit of Infectious Diseases, University of Bari ‘A. Moro’, Polyclinic Hospital, Bari, Italy
| |
Collapse
|
92
|
Hudu SA, Alshrari AS, Abu-Shoura EJI, Osman A, Jimoh AO. A Critical Review of the Prospect of Integrating Artificial Intelligence in Infectious Disease Diagnosis and Prognosis. Interdiscip Perspect Infect Dis 2025; 2025:6816002. [PMID: 40225950 PMCID: PMC11991796 DOI: 10.1155/ipid/6816002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Accepted: 02/20/2025] [Indexed: 04/15/2025] Open
Abstract
This paper explores the transformative potential of integrating artificial intelligence (AI) in the diagnosis and prognosis of infectious diseases. By analyzing diverse datasets, including clinical symptoms, laboratory results, and imaging data, AI algorithms can significantly enhance early detection and personalized treatment strategies. This paper reviews how AI-driven models improve diagnostic accuracy, predict patient outcomes, and contribute to effective disease management. It also addresses the challenges and ethical considerations associated with AI, including data privacy, algorithmic bias, and equitable access to healthcare. Highlighting case studies and recent advancements, the paper underscores AI's role in revolutionizing infectious disease management and its implications for future healthcare delivery.
Collapse
Affiliation(s)
- Shuaibu Abdullahi Hudu
- Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University, Zarqa 13110, Jordan
| | - Ahmed Subeh Alshrari
- Department of Medical Laboratory Technology, Faculty of Applied Medical Science, Northern Border University, Arar 91431, Saudi Arabia
| | | | - Amira Osman
- Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University, Zarqa 13110, Jordan
- Department of Histology and Cell Biology, Faculty of Medicine, Kafrelsheikh University, Kafr El Sheikh, Egypt
| | - Abdulgafar Olayiwola Jimoh
- Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto 840232, Sokoto State, Nigeria
| |
Collapse
|
93
|
Briseno-Ramírez J, Gómez-Quiroz A, Avila-Cardenas BB, De Arcos-Jiménez JC, Perales-Guerrero L, Andrade-Villanueva JF, Martínez-Ayala P. Development of a Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to guide empiric antibiotic treatment for ventilator-associated pneumonia in a Mexican tertiary care university hospital. BMC Infect Dis 2025; 25:307. [PMID: 40038606 PMCID: PMC11877913 DOI: 10.1186/s12879-025-10677-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2024] [Accepted: 02/18/2025] [Indexed: 03/06/2025] Open
Abstract
BACKGROUND Ventilator-associated pneumonia (VAP) is a significant nosocomial infection in critically ill patients, leading to high morbidity, mortality, and increased healthcare costs. The diversity of local microbiology and resistance patterns complicates the empirical treatment selection. The Weighted-Incidence Syndromic Combination Antibiogram (WISCA) offers an innovative tool to optimize empirical antibiotic therapy by integrating local microbiological data and resistance profiles. OBJECTIVE To develop a WISCA tailored for VAP in a Mexican tertiary care university hospital, aiming to enhance empirical antibiotic coverage by addressing the unique pathogen distribution and resistance patterns within the institution. METHODS This retrospective study included 197 VAP episodes from 129 patients admitted to a critical care unit between June 2021 and June 2024. Clinical and microbiological data, including pathogen susceptibility profiles, were analyzed using a Bayesian hierarchical model to evaluate the coverage of multiple antibiotic regimens. We also assessed the current impact of inappropriate empiric or directed treatment on in-hospital mortality using Cox regression models to support the development of a WISCA model. RESULTS The median age of the patients was 44 years (IQR 35-56), with Acinetobacter baumannii (n = 71), Enterobacterales (n = 53) and Pseudomonas aeruginosa (n = 36) identified as the most frequently isolated pathogens. The developed WISCA models showed variable coverage based on antibiotic regimens and the duration of invasive mechanical ventilation (IMV). Inappropriate directed therapy during the VAP episode was associated with increased mortality, as were the diagnosis of Acute Respiratory Distress Syndrome (ARDS) and a high Sequential Organ Failure Assessment (SOFA) score (p < 0.01). CONCLUSIONS The tailored WISCA with Bayesian hierarchical modeling provided more adaptive, subgroup-specific estimates and managed uncertainty better compared to fixed models. The implementation of this WISCA model demonstrated potential to optimize antibiotic strategies and improve clinical outcomes in critically ill patients in our hospital. TOPIC Optimizing Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia Using a Weighted-Incidence Syndromic Combination Antibiogram in a Mexican Tertiary Care Hospital.
Collapse
Affiliation(s)
- Jaime Briseno-Ramírez
- Department of Internal Medicine, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico
- Laboratory of Microbiological, Molecular, and Biochemical Diagnostics (LaDiMMB), CUTlajomulco. University of Guadalajara, Tlajomulco de Zuñiga, Mexico
- Health Division, Tlajomulco University Center, University of Guadalajara, Tlajomulco de Zuñiga, Mexico
| | - Adolfo Gómez-Quiroz
- Microbiology Laboratory, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico
| | | | - Judith Carolina De Arcos-Jiménez
- Laboratory of Microbiological, Molecular, and Biochemical Diagnostics (LaDiMMB), CUTlajomulco. University of Guadalajara, Tlajomulco de Zuñiga, Mexico
- Health Division, Tlajomulco University Center, University of Guadalajara, Tlajomulco de Zuñiga, Mexico
| | - Leonardo Perales-Guerrero
- Department of Internal Medicine, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico
| | | | - Pedro Martínez-Ayala
- HIV Unit Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, C.P. 44670, Mexico.
- Health Division, Tlajomulco University Center, University of Guadalajara, Tlajomulco de Zuñiga, Mexico.
| |
Collapse
|
94
|
Liu R, Tang L, Liu Y, Hu H, Liu J. Causal relationship between immune cell signatures and colorectal cancer: a bi-directional, two-sample mendelian randomization study. BMC Cancer 2025; 25:387. [PMID: 40033246 PMCID: PMC11877943 DOI: 10.1186/s12885-025-13576-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Accepted: 01/21/2025] [Indexed: 03/05/2025] Open
Abstract
BACKGROUND Prior studies have demonstrated the association between immune cells and colorectal cancer (CRC). However, the causal link to specific immunophenotypes is limited. This study intends to elucidate the causal relationship of immune cell signatures on CRC. METHODS We performed a bi-directional and two-sample mendelian randomization (MR) study, utilizing GWAS summary data of 731 immune cell traits (n = 3,757) and CRC statistics (n = 470,002). The primary MR methodology was inverse-variance weighted (IVW) method. Furthermore, heterogeneity was evaluated by Cochran's Q test. MR-PRESSO and MR-Egger were employed to assess horizontal and vertical pleiotropy respectively. Sensitivity analysis and FDR correction were conducted in our results. These results were validated in both the UK Biobank and FinnGen cohorts. We also extracted transcriptomic data of CRC and adjacent non-tumor tissues from TCGA, and used CIBERSORT to compare the infiltration patterns of 22 immune cell panels between normal tissues and the tumor microenvironment (TME). RESULTS Our study indicated nine immune cell signatures had significant causality with the risk of CRC after sensitivity analysis and FDR correction. The positive results covered four panels: B cell, CD8 + T cell, Treg, and monocyte. IgD- CD38br and IgD + CD38br B cell, CD8dim and CD28 + CD45RA- CD8dim T cell, and CD14 on CD14 + CD16- monocyte were the protective factors of CRC. However, CD39 + resting Treg, CX3CR1 on CD14- CD16 + monocyte, FSC-A on HLA DR + T cell, and BAFF-R on B cell increased the risk of CRC. The results were validated in the UK Biobank data and FinnGen cohorts. The data from the TCGA database also confirmed the infiltration of B cell, CD8 + T cell, Treg, and monocyte panels in the TME. CONCLUSION This study highlights the causal link between specific immune cell phenotypes and CRC, providing valuable insights into the immune microenvironment's role in CRC. The validation of our findings using large-scale datasets (UK Biobank, FinnGen) and TCGA underscores the robustness of our results, offering new potential therapeutic targets for CRC treatment.
Collapse
Affiliation(s)
- Ruizhi Liu
- School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Liansha Tang
- Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, Sichuan Province, 610041, China
| | - Yunjia Liu
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China
| | - Handan Hu
- Queen Mary College, Nanchang University, Nanchang, Jiangxi, China
| | - Jiyan Liu
- Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, Sichuan Province, 610041, China.
| |
Collapse
|
95
|
Badran B, Nawahda D, Aiesh BM, Alawneh M, Taha AA, Zyoud SH. Assessment of physicians' proficiency concerning antibiotic use for upper respiratory tract infections in children: a cross-sectional study. Sci Rep 2025; 15:7362. [PMID: 40025150 PMCID: PMC11873227 DOI: 10.1038/s41598-025-92434-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2024] [Accepted: 02/27/2025] [Indexed: 03/04/2025] Open
Abstract
Since most upper respiratory tract infections (URTIs) are caused by viruses, treatment with antibiotics is considered nonbeneficial and futile. Nonetheless, antibiotic misuse remains a concern that has a profound impact on global health, owing to the possible development of antibiotic resistance. Therefore, understanding the factors influencing physicians' practices and attitudes and assessing their level of knowledge regarding antibiotic prescriptions for children with URTIs is advisable to determine the factors that lead to the emergence of antibiotic resistance. A cross-sectional study was conducted among pediatricians and pediatric residents in the northern West Bank, Palestine, from December 2021 to the end of January 2022. Data were collected via a validated self-administered questionnaire with four sections: demographic details, knowledge (scored 0-1), attitudes (11-item Likert scale, maximum 55), and prescribing behavior for pediatric URTIs (scored 1-5, maximum 55). Statistical analysis was performed via SPSS v21, with nonparametric tests (Mann‒Whitney U, Kruskal‒Wallis) applied for nonnormal variables (p < 0.05). Demographics, knowledge, attitudes, and behaviors were summarized using frequencies, percentages, medians, and interquartile ranges. A total of 108 questionnaires were collected and returned, yielding a response rate of 90%. The overall level of knowledge among the respondents was commendable but concerning, as 22% of them mistakenly believed that antibiotics functioned as anti-inflammatory drugs. T The participants' attitudes ranged from 29 to 52 points, with a maximum possible score of 55. The average score was 41.1 ± 3.6, reflecting generally favorable attitudes toward antibiotic usage among the participants. However, 6.5% of the respondents expressed a preference for the use of broad-spectrum antibiotics for most cases of acute URTIs. The practice score also followed a normal distribution, with an average score of 35.4 ± 7.7 out of 55. Some respondents identified challenges in properly prescribing antibiotics, such as the time required to explain antibiotics to parents, parental requests for antibiotics, and uncertainty regarding the illness. The age of the respondents was significantly positively correlated with their behavioral state (p = 0.037), with older respondents exhibiting better behavioral patterns. Pediatric residents and female respondents had comparatively lower perceptions of antibiotic behavior and practices (p = 0.004 and p = 0.03, respectively). Additionally, the results revealed positive correlations between participants' attitudes and practices (rs = 0.434, p < 0.001) and between their knowledge and practices (rs = 0.355, p < 0.001). Several factors influencing physicians' practices, as well as factors related to parents, were identified. Thus, enhancing knowledge alone may not be sufficient. Possible recommendations were examined, with a focus on improving the doctor‒patient relationship and implementing essential educational interventions to increase awareness of antibiotic resistance and promote better prescribing and purchasing behaviors for both physicians and the general public.
Collapse
Affiliation(s)
- Bessan Badran
- Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine
| | - Donya Nawahda
- Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine
| | - Banan M Aiesh
- Infection Control Department, An-Najah National University Hospital, Nablus, 44839, Palestine
| | - Maysa Alawneh
- Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
- Department of Pediatrics, An-Najah National University Hospital, Nablus, 44839, Palestine.
| | - Adham Abu Taha
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
- Department of Pathology, An-Najah National University Hospital, Nablus, 44839, Palestine.
| | - Sa'ed H Zyoud
- Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine
- Clinical Research Center, An-Najah National University Hospital, Nablus, 44839, Palestine
| |
Collapse
|
96
|
Zhao J, Zhang W, Luo J, Fang H, Wang K. Clinical application of acute Q fever -induced systemic capillary leak syndrome in a patient by using metagenomic next-generation sequencing: a case report and literature review. BMC Infect Dis 2025; 25:300. [PMID: 40025420 PMCID: PMC11874829 DOI: 10.1186/s12879-025-10699-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2024] [Accepted: 02/20/2025] [Indexed: 03/04/2025] Open
Abstract
INTRODUCTION Query fever (Q fever), a zoonotic disease, caused by Coxiella burnetii, is an infectious disease that has long been considered a rare and regionally restricted disease. It can be responsible for endocarditis and endovascular infections. Systemic capillary leak syndrome (SCLS), a rare disease of unknown etiology that most commonly develops in adults 50-70 years of age, is diagnosed clinically based on a characteristic symptomatic triad of hypotension, hemoconcentration (elevated hemoglobin or hematocrit), and serum hypoalbuminemia resulting from fluid extravasation. Although Q fever has increasingly been recognized and reported in recent years, the treatment of Q fever complicated by SCLS, with an etiological diagnosis aided by metagenomic next-generation sequencing (mNGS), remains uncommon. CASE PRESENTATION This report describes a case of acute Q fever with concurrent SCLS in a 54-year-old male who worked in a slaughterhouse. The patient presented with fever, chest tightness, and shortness of breath, accompanied by severe headache. His condition rapidly deteriorated, leading to acute fever, generalized weakness, and hypotension. Due to respiratory failure and shock, he was admitted to the intensive care unit (ICU) for treatment. Despite empirical antibiotic therapy along with fluid resuscitation, his blood pressure continued to decline, and metabolic acidosis and respiratory distress worsened. As his condition failed to improve, tracheal intubation was performed. mNGS detected both Coxiella burnetii in his BALF and blood samples. Based on the mNGS results, he was started on doxycycline, alongside penicillin antibiotics, vasopressors, and continuous renal replacement therapy (CRRT). The patient's condition gradually improved, and he was discharged home after 12 days of treatment. At his 90-day follow-up, he had nearly fully recovered to his pre-illness status. CONCLUSIONS mNGS plays a crucial role in assisting the diagnosis of Q fever, which enables the timely treatment of the underlying disease triggering SCLS. This, combined with restrictive fluid resuscitation strategies, is essential for improving patient outcomes.
Collapse
Affiliation(s)
- Junjie Zhao
- Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China
| | - Weiwen Zhang
- Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, China
| | - Jian Luo
- Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, China
| | - Honglong Fang
- Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, China.
| | - Kaiyu Wang
- Department of Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, China.
| |
Collapse
|
97
|
van Delden C, Manuel O, Hirzel C, Walti LN, Khanna N, Hirsch HH, Dionyios N, Kohler P, Abela IA, Mueller NJ. The Swiss Transplant Cohort Study: Implications for Transplant Infectious Diseases Research. Transpl Infect Dis 2025; 27:e70023. [PMID: 40127403 DOI: 10.1111/tid.70023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2025] [Revised: 03/03/2025] [Accepted: 03/04/2025] [Indexed: 03/26/2025]
Abstract
The longitudinal, nationwide Swiss Transplant Cohort Study (STCS) follows > 92% of all transplant recipients with comprehensive data collection tailored to overall and organ-specific transplant outcomes. Transplant infectious disease events are assembled under the auspices of transplant ID specialists using common definitions. With over 6000 active patients and a median follow-up exceeding 6 years, the cohort offers a unique platform for understanding real-world epidemiology in transplanted patients. Beyond observational analysis, the STCS supports randomized controlled trials to address specific research questions. This overview highlights the achievements of the STCS and explores its future directions.
Collapse
Affiliation(s)
- Christian van Delden
- Transplant Infectious Diseases Unit, Service of Infectious Diseases, University Hospitals Geneva, University of Geneva, Geneva, Switzerland
| | - Oriol Manuel
- Infectious Diseases Service and Transplantation Center, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Cédric Hirzel
- Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Laura N Walti
- Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Nina Khanna
- Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Hans H Hirsch
- Department of Biomedicine Transplantation & Clinical Virology, University of Basel, Basel, Switzerland
| | - Neofytos Dionyios
- Transplant Infectious Diseases Unit, Service of Infectious Diseases, University Hospitals Geneva, University of Geneva, Geneva, Switzerland
| | - Philipp Kohler
- Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital of Sankt Gallen, St. Gallen, Switzerland
| | - Irene A Abela
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Nicolas J Mueller
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| |
Collapse
|
98
|
Gissa SB, Zewdie SD, Kindie AD, Mugoro BT, Henriksen TH. Survey and control of antimicrobial resistance: need for pragmatic options in low-resource settings. THE LANCET. MICROBE 2025; 6:101021. [PMID: 39515357 DOI: 10.1016/j.lanmic.2024.101021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Accepted: 10/11/2024] [Indexed: 11/16/2024]
Affiliation(s)
- Selam Bogale Gissa
- Department of Internal Medicine Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia
| | - Soliyana Dejene Zewdie
- Department of Internal Medicine Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia
| | - Ayelign Derebe Kindie
- Education Development Center Department Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia
| | | | - Thor-Henrik Henriksen
- Department of Internal Medicine Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia; Department of Microbiology, Vestfold Hospital Trust, Tønsberg 3103, Norway.
| |
Collapse
|
99
|
Tängdén T, Carrara E, Hellou MM, Yahav D, Paul M. Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward. Clin Microbiol Infect 2025; 31:354-359. [PMID: 39374649 DOI: 10.1016/j.cmi.2024.09.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2024] [Revised: 09/27/2024] [Accepted: 09/28/2024] [Indexed: 10/09/2024]
Abstract
BACKGROUND Following intense efforts to revive the dry antibiotic research and development pipeline, a few highly awaited antibiotics with activity against multidrug-resistant (MDR) bacteria were recently approved. OBJECTIVES We aim to highlight gaps in the evidence generated for new antibiotics by the time of their approval and to review the consequent limitations of treatment guidelines for priority MDR bacteria. We also report on the availability of the new antibiotics, reimbursement strategies allowing the use of these antibiotics in hospitals, and antibiotic stewardship efforts. SOURCES We searched PubMed for phase 3 randomized controlled trials, guidelines, and publications on access, usage, regulatory aspects and antimicrobial stewardship of antibiotics approved for use against MDR bacteria between 2013 and 2023. Other sources included governmental and professional documents regarding policies for reimbursement and use of the new antibiotics. CONTENT Several gaps in the evidence available regarding the new antibiotics are described related to the trials' target populations, comparators, management algorithm within the trial, non-inferiority hypotheses, and assessment of resistance development within the studies. We highlight the risk of current guidelines to increase the usage of new antibiotics and consequently accelerate resistance development. Updated mapping of antibiotic availability reveals critical inequality in access to the new antibiotics. Finally, strategies used nationally in Europe to provide access to the new antibiotics are not sufficiently balanced by antibiotic stewardship efforts to calibrate the judicious use of the new antibiotics. IMPLICATIONS Antibiotic resistance is an immediate threat. The present review highlights areas where more systematic and uniform strategies across countries and geographical regions are warranted to improve evidence, availability, and use of new broad-spectrum antibiotics.
Collapse
Affiliation(s)
- Thomas Tängdén
- Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden.
| | - Elena Carrara
- Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
| | - Mona Mustafa Hellou
- Infectious Diseases Institute, Rambam Healthcare Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
| | - Dafna Yahav
- Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel
| | - Mical Paul
- Infectious Diseases Institute, Rambam Healthcare Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
100
|
Diaz JJ, Napolitano L, Livingston DH, Costantini T, Inaba K, Biffl WL, Winchell R, Salim A, Coimbra R. Evidence-based, cost-effective management of acute appendicitis: An algorithm of the Journal of Trauma and Acute Care Surgery emergency general surgery algorithms work group. J Trauma Acute Care Surg 2025; 98:368-373. [PMID: 39894950 PMCID: PMC11902600 DOI: 10.1097/ta.0000000000004569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2024] [Revised: 01/22/2025] [Accepted: 12/13/2024] [Indexed: 02/04/2025]
|